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Summary 
Biodiversity was during the 1990s perceived as ‘green gold’. With the 
emergence of the biotechnology industry, biodiversity prospecting, or 
bioprospecting, was perceived to provide opportunities to gain benefits for 
several purposes. Benefits would attribute towards conservation, 
development of source countries, new medicines, profits for the industry 
and welfare to local providers of biogenetic resources and traditional 
knowledge. Biodiversity became the object of international legislation, the 
1992 Convention on Biological Diversity (CBD).  
   The Biodiversity Convention introduced several new concepts, of which 
the most important one was national sovereignty over biological resources. 
Through this, access and obligation of conservation was put under the 
control of the source country. The reason for introducing sovereign 
ownership of resources that before had been the “common heritage of 
mankind” was to enable benefit sharing, i.e. ensuring that benefits arising 
from the use of biological resources were channelled back to the source. The 
Convention further afforded protection to traditional knowledge. The level 
of protection has however, in the light of several highly-publicized 
biopiracy cases involving traditional knowledge, been the subject of an 
intense ongoing debate. The discussion has come to involve another 
international instrument, the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPs). 
     The TRIPs Agreement establishes a system of minimum protection for 
intellectual property rights. Although a minimum system for developed 
countries, this was a substantial adjustment for several developing countries 
that did not afford patent protection to the extent of the minimum 
requirements in TRIPs. However, the promise of capacity-building 
technology transfer was the bargain that developing countries got in 
exchange for entering the Agreement.  
   The relationship between the CBD and the TRIPs Agreement is an 
ongoing issue. Bioprospecting is at the heart of the intersection. Traditional 
knowledge is a form of an intellectual property right that is not provided for 
in the conventional system. Closely related to this are questions on patents 
derived from biological resources and associated knowledge and the legal 
framework for the sharing of the benefits accrued. Should benefits be shared 
when the patent is based on biogenetic material which was accessed with the 
assistance of traditional knowledge, but where the compound has been 
isolated in the laboratory and used in a product to treat a completely 
different disease than the disease envisaged by the traditional knowledge? 
And how should they be shared? 
   This thesis poses two main questions. How is biological resources and 
associated traditional knowledge protected through international and 
national legislation when it is the subject of interest in bioprospecting 
activity, and does this stimulate bioprospecting projects or do current trends 
in legislation act as a deterrent? Through an overview of legislation and, to a 
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rudimentary extent, economic theory, it tries to provide with some 
suggestive answers. 
   The thesis begins with presenting key concepts to biodiversity and 
bioprospecting in the introductory chapter. Terms like biodiversity, 
biological resources traditional knowledge (TK), prior informed consent 
(PIC) and access and benefit sharing (ABS) are briefly explained.  
  Chapter 3 gives an overview of value theories of bioprospecting and access 
and benefit sharing. It shows that the value of biodiversity is elusive, and 
dependent on how it is used. As raw material the value is less than as a piece 
that is used to create an idea. The idea itself has more value than 
biodiversity (for example as timber) but less value than an invention. 
Further it presents a market based approach to ABS where it is argued that 
the regulatory approach in current national legislations is detrimental to 
future bioprospecting projects. Bioprospecting is also put forward as cost-
saving for the government. 
   The second part of chapter 3 presents two projects that provide practical 
examples. 
   In chapter 4 the international framework for patent protection and 
biodiversity conservation and sustainable use presented. The relevant 
articles in TRIPs and the CBD are presented as well as voluntary guidelines 
and codes of conduct.  
   Chapter 5 elaborates on the relationship between the TRIPs Agreement 
and the CBD. It is established that while there is no direct relation between 
IPRs and conservation of biodiversity, IPRs nevertheless form part of the 
economic and social context in which conservation takes place. Intellectual 
property rights are relevant for the crafting of ABS arrangements relating to 
equity. Furthermore, the chapter gives an overview of the differing opinions 
of developing contra developed countries, reflected through discussions in 
the TRIPs Council. Mainly developing countries are pressing for a 
requirement of prior informed consent which would be mandatory in patent 
application. Developed countries, with the US on the front line, oppose such 
requirements stating that the intellectual property system is not the right 
forum to solve issues of biopiracy and ABS.  
   Chapter 6 is devoted to describing and comparing two national (the 
Philippines and Costa Rica) and two regional (the Andean Community and 
the Organization of African Unity (OAU)) ABS instruments. When looking 
closer at regional and national regimes no one model emerges, rather there 
are considerable variations. Different cultural and legal systems require 
adaptation to local conditions. It is also possible that the time at which the 
legislation was adopted plays a significant role. The Philippine who was the 
first to enact ABS legislation opted not to include provisions on intellectual 
property while the OAU has very explicit provisions on traditional 
knowledge, perhaps reflecting the discussion in the TRIPs Council.  
   Chapter 7 further analyzes the somewhat ambivalent view of the European 
Community on traditional knowledge and ABS. Given the importance of the 
biotechnology industry for the development of economic growth in Europe 
it is perhaps not strange that the EC is reluctant to introduce any constraints 
on intellectual property rights. Nevertheless, the EC has supported the Swiss 
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proposal to introduce a disclosure requirement in the Patent Cooperation 
Treaty which governs international patent applications.   
   Chapter 8, the analysis and the conclusion in chapter 9 suggests an 
appropriate trade-off between stimulating third generation biotechnology 
(genetic engineering techniques), on the more advanced level of research, 
and stricter application of the patentability criteria (i.e. novelty, inventive 
step and industrial application) to patent applications relating to “raw” 
material such as biological resources and associated TK. Otherwise the 
tightened IPR regime that is imposed on developing countries through the 
implementation of the TRIPs Agreement will aggravate biodiversity 
conservation and the maintenance of traditional knowledge relating to 
biodiversity. Further it is suggested that the biodiversity-rich countries 
(mainly the South) are trying to compensate for the non-stringency of the 
industrialized (North) countries’ intellectual property rights legislation, 
thereby implementing restrictive rules that unintentionally hinders scientific 
research. This could be remedied through the fulfilment of the commitment 
of developed countries to provide for technology transfer to developing 
countries. In the creation of a viable technological platform for the 
developing countries to take advantage of the patent system under TRIPs, 
domestic traditional knowledge could receive adequate protection. In the 
end, bioprospecting is dependent on the achievement of good faith.   
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Abbreviations and Acronyms 
ABS  Access and Benefit Sharing 
APEC  the Asia-Pacific Economic Cooperation 
ARA  Academic Research Agreement 
CBD  the Convention on Biological Diversity 
COP  the Conference of the Parties (to the CBD) 
CRA  Commercial Research Agreement 
DENR Department of Environment and Natural 
Resources 
EO  Executive Order 
EPC the European Patent Convention 
EPO the European Patent Office 
FAO the Food and Agriculture Organization of the 
United Nations 
GRULAC the Group of Countries of Latin America and the 
Caribbean 
GSK  GlaxoSmithKline 
ICBG International Cooperative Biodiversity Groups 
ICTSD the International Centre for Trade and 
Sustainable Development 
INBio Instituto Nacional de Biodiversidad (National 
Biodiversity Institute, Costa Rica) 
ISE  the International Society of Ethnobiology 
IUCN the International Union for the Conservation of 
Nature and Natural Resources (the World 
Conservation Union) 
MOSAICC the Micro-Organisms Sustainable Use and 
Access Regulation, International Code of 
Conduct 
MTA  Material Transfer Agreement  
NAFTA  the North America Free Trade Association 
OAU  the Organization for African Unity 
PhRMA the Pharmaceutical Research and Manufacturers 
of America 
PIC  prior informed consent  
RAFI  the Rural Advancement Foundation International 
TK  traditional knowledge 
TRIPs Agreement on Trade-related Aspects of 
Intellectual Property Rights 
UNCTAD the United Nations Conference on Trade and 
Development 
UPOV Union International pour la Protection des 
Obtentions Végétales (International Union for 
the Protection of New Varieties of Plants)  
WIPO  the World Intellectual Property Organization 
WTO  the World Trade Organization 
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1 Introduction 
What is bioprospecting and why has it been the focus of so much attention 
over the last years? 
   Biodiversity prospecting was the title of a book published in 1993 by 
Walter Reid and co-authors. With that book the term bioprospecting was 
coined, and it was soon reciprocated by the responding term biopiracy. 
Simply put, bioprospecting is the search, collection and screening of 
biological material1 and/or traditional knowledge (hereinafter TK) for 
commercial ends, with particular reference to the pharmaceutical, 
biotechnological and agricultural industries.2 Biopiracy was coined by the 
Rural Advancement Foundation International (RAFI) as a response to the 
depicted win-win scenario championed in the book and implied by the term 
bioprospecting.3 Instead of the promising picture of mutually beneficial 
contracts, biopiracy reflects the impossibility of such contracts due to the 
current socio-economic environment.4
   Biopiracy is not a uniform concept per se. Rather; one can distinguish 
between two main “clusters” of biopiracy opponents. There are those who 
recognize a difference between the two terms; bioprospecting does not 
necessarily mean biopiracy. Instead, bioprospecting is seen as the search for 
commercially useful biological material and/or associated knowledge while 
biopiracy is the appropriation of such resources without prior consent and 
fair compensation. From this perspective bioprospecting is the primary step 
which may or may not be followed by the second illegal step of biopiracy. 
   Another more radical position equates bioprospecting with biopiracy, 
thereby entirely denouncing the concept of bioprospecting. In other words; 
there is no bioprospecting, only biopiracy. 
   The opinions on how important bioprospecting is for the advancement of 
new pharmaceuticals differ greatly. Plotkin, an ethnobotanist currently the 
president of Amazon Conservation Team, sees a great future for biological 
material as basis for new medicines. According to him:  
 
“Synthetic drugs will continue to play a major role in the 
market place, but natural and semisynthetic medicines (based on chemicals 
that occur in nature that have been manipulated or duplicated in the lab) 
will increase in importance for the foreseeable future.”5
    
                                                 
1 For the purpose of this thesis the term biological resources/material will be used as a 
comprehensive term, including genetic resources. See below, chapter 1.3. 
2 Dutfield, ‘Bioprospecting: legitimate research or biopiracy?’, revised version 2002, 
Science and Development Network, 
http://www.scidev.net/dossiers/index.cfm?fuseaction=printarticle&dossier=7&policy=40, 
24/04/06. 
3 Mooney, ‘Why we call it biopiracy’, in Svarstad and Dhillion (eds), Bioprospecting: 
From biodiversity in the South to medicines in the North, 2000, p. 37. 
4 Ibid. 
5 Plotkin, Medicine Quest: In search of Nature’s Healing Secrets, 2000, p. 22. 
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Another argument for the increasing value of natural compounds is the 
possibility, with the advancement of technology, to extract the potent 
compound and change it slightly to make it more or less toxic or to remove 
any unwanted side effects. In other words, chemists can use the molecule of 
interest and use it as a brick in order to construct something completely 
new. The chemical structure of the natural compound is often to complex to 
be thought of by a synthetic organic chemist. An example of this would be 
Taxol, an anti-cancer compound derived from the yew tree.6
As Plotkin has stated: 
 
“…the value of nature as a source of novel compounds with 
therapeutic applications increases (rather than diminishes) as technology 
advances.”7
 
Not only plants offer promises of new drugs. Different poisons, both toxins 
and venoms, form the basis for pharmaceutical research. The drug Capoten, 
used to treat hypertension, was developed based on research on the Brazilian 
viper venom.8 Another example is Botox, a cosmetic substance used for 
anti-wrinkle treatments which consists of small amounts of the deadly 
botulism bacteria. When injected into the facial muscles, it causes temporary 
paralysis, resulting in a surgeyless face-lift.9
   Biological material exploited as pharmaceutical remedies is perhaps what 
first comes to mind when envisaging the concept of bioprospecting. 
However, biological resources present more fields of use. There is an 
increasing interest in biological organisms that can function as cleaners of 
toxic waste, perform in high temperatures in industrial processes or as 
inspiration for the design of new tools. One example is the microorganism 
Thermus aquaticus, discovered in the thermal pools of Yellowstone 
National Park. This microorganism contains an enzyme which has 
revolutionized genetic research. It forms the basis of PCR (polymerase 
chain reaction) which gives the researchers the ability to, from a tiny DNA 
sample such as a hair, duplicate and copy large numbers of the DNA for the 
researchers to analyze.10  
   Why then, if bioprospecting has such great potential, has it come under so 
much negative attention? As inferred above, the issue has larger 
implications than it first may seem. It is not simply a question of legislating 
to solve issues of ownership and intellectual property rights (hereinafter 
IPRs) but it has highlighted the on-going conflict between the developed 
North and the developing South. The bioprospecting activity cannot be 
separated from the divisive issue of global economic disparities, 
characterizing the relationship between North and South. The Convention 
on Biological Diversity (hereinafter CBD), and the Agreement on Trade-
related Aspects (hereinafter TRIPs), international agreements that will be 
surveyed in this thesis, are both the result of negotiations where this 
                                                 
6 Plotkin, 2000, p. 28. 
7 Ibid, p. 29. 
8 Ibid, p. 7. 
9 Ibid, p. 8. 
10 Ibid, p. 34. 
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relationship had to be balanced. In the CBD the developing countries 
received sovereign rights over their biological resources that previously 
were considered “common heritage of mankind” and developed countries 
got facilitated access to those resources and recognition of IPRs.11 In TRIPs, 
developing countries made the concession of providing for IP protection in 
exchange for the promise of transfer of technology. 
   Biodiversity exists everywhere however, it is generally said that the South 
is more biodiversity-rich than the North. 17-19 countries12 are often referred 
to as megadiverse countries as they alone harbour 60 to 70 percent of the 
world’s biodiversity. A few of those will be closer scrutinized here. Closely 
related to biodiversity and biological resources is the TK which can provide 
important leads when exploring biodiversity. Another important function is 
to cover the health need of an estimated one third of the world’s population. 
On the African continent around 80 percent of the population relies on 
traditional remedies for their primary health need.13 As such, TK has a value 
both as source of information for research and development (hereinafter 
R&D) but also as already developed knowledge used in daily life. Arguably, 
the issue of protection afforded to biological resources and traditional 
knowledge becomes important, especially as TK is a “strange bird” in the 
IPR system under TRIPs. The question therefore arises whether the IPR 
system is supporting and facilitating the procurement of the vital necessities 
for people or if it renders it more difficult.  
   This issue is not only a matter of legal concern, but it also reflects the 
conflicts between the “rich” North and the “poor” South, the clash of 
different belief systems and perspectives on life and society. 
 
1.1 Purpose and Delimitations 
The main question guiding me throughout this thesis is how biological 
resources and associated TK is protected through international and national 
legislation when it is the subject of interest in bioprospecting activity, and 
whether this stimulates bioprospecting projects or if current trends in 
legislation act as a deterrent. A related question is if the conflicts in this area 
would subside if the existing IPR system was to be applied correctly, 
meaning applying the patentability criteria more restrictively. Or is it, as 
many will argue, that our current western patenting system does not provide 
for this kind of material and knowledge?  
   As implied above, the question of protection of these resources cannot be 
separately analyzed from issues of access and benefit sharing (hereinafter 
ABS) or capacity building and technology transfer. Consequently, it has 
                                                 
11 For an overview of the trade-offs between industrialized and developing countries, see 
McGraw, ‘The Story of the Biodiversity Convention: From Negotiation to 
Implementation’, in Le Prestre (ed), Governing Global Biodiversity, 2004, pp 29-32. 
12 They are: Bolivia, Brazil, China, Colombia, Costa Rica, Democratic Republic of Congo, 
Ecuador, India, Indonesia, Kenya, Madagascar, Malaysia, Mexico, Peru, Philippines, South 
Africa, and Venezuela. Australia and the USA are additionally included. 
13 WHO Fact sheet No 134, revised version 2003, 
http://www.who.int/mediacentre/factsheets/fs134/en/, 25/04/06. 
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been an equal purpose of the author to closer analyze the legal provisions 
governing these issues as well as to offer a rudimentary economic setting to 
biodiversity, TK and ABS.                                                                                                                      
   This thesis deals with TK, which can lead to patents. The initiated reader 
knows that this is only a small part of what can be said to constitute TK. 
Other forms of IPRs, for example trademarks or copyrights, have been left 
outside the scope of the thesis. 
   Patents themselves have been subject to further limitation in scope. 
Although protection for plant varieties is highly relevant and related to the 
questions dealt with here, I have chosen to exclude it. This means that sui 
generis systems such as the regime under UPOV, is excluded. 
Consequently, I only discuss patents and trade secrets concerning the 
biological resources and the associated TK for pharmaceutical and, to some 
extent, natural remedy purposes.  
   The different concepts that international and national legal instruments 
(together with voluntary guidelines, of which some are presented in the 
thesis) orbit around are essential to the subject at hand. The presentation of 
these is however not exhaustive, there is enough material and subsequent 
debate concerning the full definitions of the terms and to what extent they 
are fully covered in the law. The scope of this thesis only allows a general 
overview. 
   In the chapter on national ABS legislation I have chosen two national laws 
that are in force and two model legislations that reflects the aims of regional 
entities. As of now there are only three national legislations in force, the 
Philippine EO 247, the Costa Rica Biodiversity law and the Brazilian 
Provisional Measure No. 2-186-16 of August 23, 2001. Both the Philippine 
and Brazilian legislations are not enacted by the legislative assembly, 
possible to repeal with a Presidential Order. When presenting the national 
ABS laws I have chosen to refer to articles and parts of articles that I have 
deemed relevant to this essay. This means for instance that some of the 
mutually agreed terms conditioned in the Costa Rican Biodiversity Law 
have been omitted.  
 
1.2 Method and Material  
The traditional legal dogmatic approach has been used in this thesis together 
with a comparative method in the chapter on national and regional ABS 
legislation. The thesis addresses two international legal instruments, one 
dealing with intellectual property and technology transfer (the TRIPs 
Agreement) and the other with conservation and sustainable use of 
biodiversity (the CBD). Relevant articles in these instruments are explained 
and scrutinized. The second step has been to explore the relationship 
between the two and to closer analyze a number of regional and national 
legal instruments.  
   When selecting the regional and national legislation intended for further 
analysis, it was availability of English translations, chronological adoption 
of the legislation and ampleness of written information on the instruments 
that were the selective criteria. Thus, the Philippine ABS legislation was the 
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first to be adopted and the Costa Rican Biodiversity Law has received much 
attention as Costa Rica has extensive experience with bioprospecting 
contracts. The Andean Community was also quick to adopt a regional 
decision with several megadiverse countries as members while the 
Organization for African Unity (hereinafter the OAU) with its Model Law 
provides an example of a framework meant to cater for multi-cultural and 
national diversity. The GRAIN website has been the source of the English 
translations. 
   In order to obtain a conceptual overview I have had to go beyond the legal 
literature. Bioprospecting enlists legal experts, chemists, ethnobotanists, 
activists, economists; the list can be made long. The suggestive 
interdisciplinary analysis provided is, in the author’s opinion, of particular 
value to this area of legal research.  
   
1.2.1 Discourse analysis 
As a part of the analysis I have had to strike a balance between the two 
different discourses mainly present in literature and articles. A useful theory 
to navigate by has been the discourse analysis. It focuses not directly on the 
phenomenon, in this case access to biological resources and TK itself, but 
on the claims concerning the phenomenon, the claims-makers and the 
claims-making process.14 Different patterns of expressions used are 
identified.  
   Discourses contain a corpus of statements that are homogenous in 
expression. The homogeneity implies that the statements are based on 
common knowledge and perception of the issue in question. Metaphors are 
used to describe a complex situation in few or a single word.15
   Almost all literature on the subject of bioprospecting can be divided into 
two camps: 
 
• the bioprospecting proponent’s discourse; or  
• the biopiracy opponent’s discourse. 
 
The same event is often, depending on which of these two discourses the 
narrator belongs to, described very differently. 
   Simply put, the bioprospecting advocate sees bioprospecting as an activity 
that may contribute to the conservation and sustainable use of biodiversity 
and, in particular, the fair and equitable sharing of benefits from the use of 
biological resources.16 New medicines are lying out there to be discovered 
and both patients, industry, local providers of resources such as TK and the 
provider country will profit. 
   The narratives within this discourse are fundamentally positive; 
bioprospecting is seen as one of the answers to loss of biodiversity and the 
                                                 
14 Svarstad, ‘Reciprocity, biopiracy, heroes, villains and victims’, in Svarstad and Dhillion 
(eds), 2000, p. 19-20. 
15 For an analytical framework see e.g. Foucault, ‘Politics and the Study of Discourse’ in 
Burchell et al. (eds), The Foucault Effect- Studies in Governmentality, 1991. 
16 Svarstad, supra f.n.15, p. 21. 
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need for capacity building in biodiversity-rich poorer countries. Quite often 
the stories are presented by the involved actors themselves, such as Diversa 
Corporation, presented further below, Shaman Pharmaceuticals17 (now in 
bankruptcy), or ICBG18.  The term bioprospector is at the heart of the 
discourse, signalling an explorer, sent out to the wilderness to discover new 
medicines for the good of mankind.  
   Opposed to the bioprospecting concept stands the metaphor of biopiracy. 
Essentially, the biopiracy opponent sees the exploration of biodiversity for 
commercially valuable genetic and biochemical resources as biopiracy. The 
same activity is thus given a radically different association. 
   This discourse is represented by several NGOs, such as GRAIN or RAFI. 
Another famous opponent to bioprospecting is the Indian activist Vandana 
Shiva who in several publications has compared modern bioprospecting and 
western IPRs system to the brutal colonization and imperialism of old 
times.19 In her book, Biopiracy – The Plunder of Nature and Knowledge, 
she writes: 
At the heart of Columbus’ ‘discovery’ was the treatment of 
 piracy as a natural right of the colonizer…Biopiracy is the Columbian 
‘discovery’ 500 years after Columbus.20
 
The biopiracy discourse is often concentrated on selected cases that are seen 
as indicative of the phenomenon as such. Such cases would be the Neem 
tree21, the Madagaskar rosy periwinkle22 or the Hoodia23 plant. Typically 
the cases relate to patents that are perceived as a tool of the rich North to 
exploit the poor South, with indigenous communities caught in the middle, 
stripped of their knowledge without fair compensation or the possibility to 
preserve their TK for future generations.          
   The criticism against IPRs is a central issue. IPRs are not perceived as 
incentives for innovation but rather it restricts knowledge sharing and 
                                                 
17 See e.g. King and Carlson et al., ‘Issues in the commercialization of medicinal plants’, in 
Svarstad and Dhillion (eds), 2000, or Clapp and Crook, Drowning in the Magic Well: 
Shaman Pharmaceuticals and the Elusive Value of Traditional Knowledge, Journal of 
Environment and Development, 2002, Vol. 11, No.1, pp. 79-102. 
18 International Cooperative Biodiversity Groups, see e.g. Berlin and Berlin, NGOs and the 
process of prior informed consent in bioprospecting research: the Maya ICBG project in 
Chiapas, Mexico, The International Social Science Journal, 2003, Vol. 55, Iss. 4, pp. 629-
638. 
19 Moreover, she denies any need for patent protection as it does not stimulate scientific 
creativity and invention but rather is a tool for market control.  
20 Shiva, 1998, Biopiracy – The Plunder of Nature and Knowledge, p. 11.  
21 Used traditionally in India as a natural pesticide, medicine and fertilizer. Several patents 
were awarded to various Neem products. In 2000, one such patent was revoked by the EPO 
after being challenged by Indian scientists and several NGOs.  
22 In the 1950s and 60s, research scientists from Eli Lilly, enlisted by NCI, extracted two 
compounds, vincristine and vinblastine from the rosy periwinkle after being guided by 
traditional medicine using the plant to treat diabetes. The compounds turned out to be 
powerful anti-cancer drugs, earning Eli Lilly $100 million annually by 1985. No royalty has 
been paid to Madagaskar or the suppliers of the original knowledge.    
23 This cactus is traditionally used by the San people to suppress hunger and thirst. South 
Africa’s Council for Scientific Research isolated the active agent and licensed it to the 
British company Phytopharm which licensed it further to Pfizer for $32 million. No 
royalties were paid to the San.      
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curtails freedom to (re)create. And above all, TK is not something that 
would fit into or should be adapted to that system, due to its nature per se. 
Both bioprospecting proponents and biopiracy opponents advocate values 
where the well-being of people and the importance of biodiversity 
conservation in developing countries are central. The discrepancy lies in 
how these values are perceived to best be reached and what means that are 
to be employed. 
   As perhaps already apparent when reading the title of this work, it is the 
author’s view that bioprospecting is a possible concept. Biopiracy can be 
avoided, not only through complying with national legislation, but taking 
one step further and applying the broad concept of prior informed consent 
(explained further below). The author has continually throughout this work 
taken due care and attention when assessing available material, to uphold a 
satisfactory academic standard.    
 
1.3 Key Concepts in Biodiversity and 
Bioprospecting 
To facilitate understanding of the issue at hand it is helpful to get a general 
overview of the terms that are used in legislation and literature. Hence the 
key concepts that are discussed in the thesis are presented here.    
 
1.3.1 Definitions under the CBD 
Article 2 of the CBD encompasses the important definitions for the purpose 
of the Convention. Notwithstanding the limited scope of the definitions, 
they are useful when considering different aspects of bioprospecting as the 
different terms generally have a similar tenor when used elsewhere.  
   The Article defines “Biological diversity” as: 
 
The variability among living organisms from all sources, inter 
 alia, terrestrial, marine and other aquatic ecosystems and the ecological 
complexes of which they are part: this includes diversity within species, 
between species and of ecosystems. 
 
Further, for the interest of this thesis, the terms biological and genetic 
resources and material are also defined as well as biotechnology. 
   “Biological resources”24: 
 
…includes genetic resources, organisms or parts thereof, 
 populations, or any other biotic component of ecosystems with actual or 
potential value for humanity. 
   
                                                 
24 For the purpose of this thesis, biological resources and biogenetic resources are used 
interchangeably. 
 11
   “Genetic material”: 
…means any material of plant, animal, microbial or other 
origin containing functional units of heredity. 
 
   “Genetic resources”: 
 …means genetic material of actual or potential value. 
 
The CBD Article 2 additionally defines the term “Biotechnology” as: 
 
…any technological application that uses biological systems, 
living organisms, or derivatives thereof, to make or modify 
products or processes for specific use.  
 
1.3.2 Traditional knowledge 
Traditional knowledge (TK) is generally used as a generic term for 
traditional cultural expression, relevant for this presentation e.g. knowledge, 
innovation and practices. It comprises of both aesthetic and useful elements. 
Categories include, inter alia, expressions of folklore, for example cultural 
handicrafts, designs, music and dance; elements of language; agricultural 
knowledge and medicinal knowledge.25
   A distinction is made between ‘traditional knowledge’ and ‘indigenous 
knowledge’. Indigenous knowledge is a subset within the traditional 
knowledge category: indigenous knowledge is traditional knowledge held 
and used by communities, peoples and nations that are indigenous.26
Although the individual may hold TK, the individual’s right to it is 
collectively determined.27
 
1.3.3 Prior informed consent 
There is relative consensus in the literature and in national legislation on 
ABS that prior informed consent (hereinafter PIC) can be defined as the 
consent to an activity that is given after receiving full disclosure regarding 
the reasons for the activity, the specific procedures the activity would entail, 
the potential risks involved, and the full implications that can realistically be 
                                                 
25 van Overwalle, Protecting and sharing biodiversity and traditional knowledge: 
Holder and user tools, Ecological Economics, 2005, Vol. 53, pp. 585– 607, at p. 586. 
26 Intellectual property needs and expectations of traditional knowledge holders (WIPO 
Report on Fact-finding Missions on Intellectual Property and Traditional Knowledge— 
1998–1999), Geneva 2001, p. 25. 
27 Report of the UNCTAD-Commonwealth Secretariat Workshop on Elements of National 
Sui Generis Sytems for the Preservation, Protection and Promotion of Traditional 
Knowledge, Innovation and Practices and Options for an International Framework, Geneva 
4-6 February, 2004, unedited version, p. 11.  
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foreseen. Prior informed consent implies the right to stop the activity from 
proceeding, and for it to be halted if it is already underway.28  
The subsequent question of from whom the consent must be obtained and 
under which circumstances is slightly more complicated and will be further 
elaborated upon in chapter 4. 
    
1.3.4 Access and benefit sharing (ABS) 
Access and benefit sharing comprises of two separate but inextricably linked 
concepts. Access refers to the entry/bioprospecting/collection/removal of 
biological resources and/or TK.  
   Benefit sharing is usually the condition for access. It was introduced as a 
concept in the CBD and could be compared to the concept of technology 
transfer in Article 66.2 of the TRIPs Agreement29. Benefit sharing is fair 
and equitable sharing of the benefits arising from the utilization of 
biological resources, which is based on the idea of utilization and means 
much more than just ”payment” for access.30 The benefits can be monetary 
and non-monetary, short-term, medium- and long-term. Non-monetary 
benefits can for example be the sharing of R&D results and participation in 
product development. Moreover, capacity-building, both institutional and in 
human resources to help strengthening the capacities for technology 
transfer, can form part of the ABS terms.31
 
1.3.5 Mutually agreed terms 
According to Article 15 (4) CBD, access to biological resources, where 
granted, shall be on mutually agreed terms. The mutually agreed terms are 
pursued under national law. Normally, they entail a consultation process 
with the designated State Authority and, if national law requires, 
consultation with indigenous/local communities. This usually is 
accomplished through an application and the concluding of an ABS 
contract.  
                                                 
28 Darryl, A. Posey, Graham Dutfield, Beyond Intellectual Property, Toward Traditional 
Resource Rights for Indigenous Peoples and Local Communities, 1996, International 
Development Research Centre, Ottawa. 
29 Article 66.2 states that “Developed country Members shall provide incentives to 
enterprises and institutions in their territories for the purpose of promoting and 
encouraging technology transfer to least-developed country Members in order to enable 
them to create a sound and viable technological base.” This was seen by many developing 
countries as “part of the bargain” in which they agreed to provide for IP protection. 
30 Medaglia, A Comparative Analysis on The Legislation And Practices on Access to 
Genetic Resources and Benefit Sharing (ABS): Critical Aspects for Implementation and 
Interpretation, p. 213. Available at:  
http://www.iucn.org/themes/law/absdocuments/eng_critical_aspects.pdf, 27/04/06. 
31 The Bonn Guidelines on Access to Genetic Resources and Fair and Equitable Sharing of 
the Benefits Arising out of their Utilization, COP Decision VI/24, presents a suggestive list 
on possible monetary and non-monetary benefits in Appendix II. 
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The Bonn Guidelines32 provides an indicative list on mutually agreed terms 
in contracts. These include, inter alia; 
• type and quantity of genetic resources and any limitations on the 
possible use of the material;  
• capacity-building in various areas;  
• a clause on whether the terms of the agreement in certain 
circumstances (e.g. change of use) can be renegotiated;  
• whether the TK of indigenous and local communities have been 
respected, preserved and maintained, and whether the customary use 
of biological resources in accordance with traditional practices has 
been protected and encouraged;  
• treatment of confidential information;  
• provisions regarding the sharing of benefits arising from the 
commercial and other utilization of genetic resources and their 
derivatives and products.33  
 
 
                                                 
32 The Bonn Guidelines on Access to Genetic Resources and Fair and Equitable Sharing of 
the Benefits Arising out of their Utilization, COP Decision VI/24.  
33 The Bonn Guidelines, chapter IV, section D, para. 44. 
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2 The Value of Bioprospecting  
The opinions on the importance of biological resources for health, food and 
agriculture and the related TK for the global economy differ greatly. 
   There are a number of studies trying to estimate the market value of those 
resources, particularly the pharmaceutical sector and its related botanical 
medicine industry.34 One estimate is that between 1989 and 1995, 60 
percent of new anti-cancer and anti-infective drugs were of natural origin. 
If, as Farnsworth’s research suggests, 74 percent of the 119 plant-based 
compounds used in medicine worldwide has the same or related use as the 
traditional medicinal plants from which they derived, TK was likely used by 
the bioprospectors and the pharmaceutical companies in their product 
development.35
   The question however remains. Despite the obvious earlier value of 
biological resources and TK, it is difficult to predict the future of that value. 
The case of Shaman Pharmaceuticals provides an argument for the 
questionable value of at least TK. However, this is only applicable in the 
field of conventional pharmaceuticals. The field of botanical medicine is 
growing in the developed world and it is well established in countries with a 
traditional health system such as India or China. Much of the developing 
world is in fact depending on medicinal plants and their related TK.36   
 
2.1 Economic theory 
To understand the complex issue of bioprospecting and to obtain a clearer 
understanding of the mechanisms that are affected by legislation, the 
economic nature of biodiversity in general and bioprospecting in particular 
should be assessed. 
  
2.1.1 The economic nature of biodiversity in 
bioprospecting 
Simply put, natural resources are ‘common pool goods’. One user’s 
consumption subtracts from the supply but, due to the nature of the resource 
it can be difficult to exclude users. In economic terms this is referred to as 
public goods. Biological material is part of a value chain that can produce 
                                                 
34 See for example ten Kate and Laird, The commercial use of biodiversity…, 2002, 
Principe, Economics and Medicinal Plants, 1998, Cragg et al, Natural Products in Drug 
Discovery and Development, 1997 and Farnsworth, Screening plants for New Medicines, 
1988. 
35 Dutfield, Intellectual Property, Biogenetic Resources and Traditional Knowledge, 2004, 
pp. 18-19. 
36 WHO Fact sheet No 134, revised version 2003, 
http://www.who.int/mediacentre/factsheets/fs134/en/, 27/04/06. 
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what is referred to as ‘other’37 goods and services however, until the 
biological material is used as input into the production of ‘other’ goods and 
services, biodiversity constitutes common pool goods.38  
Bioprospecting activities differ from other harvesting activities. Polski 
identifies in her article three types of bioprospectors, the knowledge creator, 
the entrepreneur and the collector. They all have distinct but often 
overlapping objectives as the table below shows. 
 
Table 1 
Bioprospectors and their purposes 
 
Purpose   Knowledge Entrepreneur Collector Activity 
  Creator 
 
Advance knowledge  Yes  Yes  No  Dynamic 
Solve problems  Maybe  Yes  No  Dynamic 
Create new products, 
processes, applications Maybe  Yes  No  Dynamic 
Develop profitable 
products  Maybe  Yes  No  Dynamic 
Expand collection  Maybe  Maybe  Yes  Static 
Sell specimen to others No  Maybe  Yes  Static 
 
 
Knowledge creators, such as shamans or scientists bioprospect to create or 
advance knew knowledge. In that process they may come up with new 
products or applications and add to collections but the primary objective 
harvesting from biodiversity for the advancement of knowledge and to solve 
problems which in economic terms is quite different from simply harvesting 
a commodity from nature. The entrepreneur is primarily interested in 
building business and to develop profitable products. The collector on the 
other hand utilizes biological resources for immediate consumption, to add 
to a collection or to sell to others. The added economic value is thus not 
large and rather static in comparison to the knowledge creator’s or 
entrepreneur’s bioprospecting activities that are multidimensional in 
purpose and involve both static and dynamic economic activities.39  
   In contrast to biological resources as common pool goods, the new or 
added knowledge are private goods per se. It remains so until the holder 
chooses to share it. Products stemming from that knowledge are also private 
goods until the inventor relinquishes control over production. 
    In connection to this, one must recognize the relative value of 
biodiversity and in extension TK. Biological resources may have one value 
as a static commodity, or the potential input into creative processes, and 
                                                 
37 For instance pharmaceuticals, furniture, energy, religious practice, recreation, soil 
stabilization, food, et cetera. 
38 Polski, The institutional economics of biodiversity, biological materials and 
bioprospecting, Ecological Economics, 2005, Vol. 53, p. 546. 
39 Ibid, p. 547. Static activity is, like Table 1 suggests, one-dimensional, intended for 
immediate consumption, adding little economic value to that which is consumed. Dynamic 
activity on the other hand is value-adding, creating new knowledge and new products. It 
arguably follows that static activity is easier to calculate the value of.  
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another value when put in the hands of an experienced knowledge creator or 
entrepreneur. That is also the case with the idea contra an invention. The 
idea could have many possible applications but is not as specific as an 
invention. To estimate the value of an idea is therefore more difficult, until 
it is disseminated into inventions or products. The value of the invention can 
be estimated but cannot be fully known until it too is fully disseminated.40
   The process of knowledge creation is defined as a high risk inter-temporal 
asset transformation process. The extraction of economic value is heavily 
dependent on the possibility of assigning property rights to the products of 
the process. The economic value of knowledge is however not static but it 
changes as it develops and is transformed into inventions. Three different 
kind of economic goods can be distinguished: the biological resource; the 
idea; and the invention. 
   The obvious example of this process would be the drug discovery process. 
Typically, only one in every five thousand component researched reaches 
the market. It takes on average ten years at the cost of 800 million US$.41 
Fewer than fifteen percent of the marketed drugs generate enough revenue 
to recover the R&D costs.42
   The answer to the question on how to best form incentives and how to 
govern bioprospecting activity is founded on the economic nature of 
biodiversity, biological resources and bioprospecting. Polski suggests that a 
relational contracting basis adapted for the individual case and involving 
key stakeholders, who have an interest in the resource system where the 
bioprospecting activity occurs, is the best way to ensure success and the 
objectives of the different stakeholders. Nevertheless, much uncertainty 
remains as the empirical project examples are quite few and have yet to 
bring forth any commercialized product.43 Accrued benefits are often 
characterized as ‘spillovers’ from the R&D process, such as transfer of 
equipment and know-how and local capacity building.44     
 
2.1.2 A market-based approach to ABS 
Presently, the international community are in debate on whether access to 
biological resources and benefit-sharing regimes should be implemented 
with a regulatory approach with strict rules to guarantee that benefits are 
distributed fairly. This approach is however not shared by everyone. A study 
from the Australian APEC45 Study Centre, sponsored by PhRMA46, 
advocates a market-oriented approach, based on a clear delineation of 
property rights and developed in an international non-binding regime. 
                                                 
40 Polski, 2005, p. 548. 
41 Information from PhRMA website: http://www.phrma.org/innovation/, 11/04/06. 
42 Standard and Poor’s Corporation, 2003, Industry Survey on Healthcare: Pharmaceuticals, 
June 26, New York. 
43 However, see the example of Diversa Corporation below. 
44 Polski, 2005, p. 554.   
45 The Asia-Pacific Economic Cooperation.    
46 The Pharmaceutical Research and Manufacturers of America. 
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The main argument against the highly regulatory approach is that concerns 
regarding biopiracy have been exaggerated. The assumption that biological 
resources from biodiversity-rich countries would constitute ‘green gold’ is 
misguided and to limit access will inhibit the already failing bioprospecting 
activity and ultimately any benefits to share. Involvement by the private 
sector supporting research provides benefits for the country, North or South, 
in helping to discover and document biodiversity. Research collaborations 
between research institutions and the private sector in bioprospecting 
projects mean reduced costs for the government.47  
   Biotech-industry is regarded as the future solution to problems of 
development and conservation. It holds the promise of future 
pharmaceuticals and improvements to agriculture. The need for facilitated 
access to genetic resources is vital for this industry and any discouraging 
measures would work to a disadvantage for the country itself.48  
   ‘Good practice’ in regulation is ensuring that costs of compliance are not 
greater than the benefits deriving from the activity being regulated. 
Generally it can be said that compulsory compliance of government 
regulation is the most onerous form while voluntary compliance of 
guidelines is the least onerous form.49 It is argued that if a regulatory 
approach is undertaken in the bioprospecting area; due to low activity and 
an industry in the early stages of development, the full costs will never be 
known as regulation effectively will stop the activity almost entirely. 
Overlapping rules, e.g. requiring different permits from different 
government agencies for the same project, also constitutes an onerous aspect 
of the regulatory approach.50  
   The market-based approach is strongly opposed to introducing additional 
conditions for patent applications. IPRs (in this thesis mainly patents) are 
fundamental for the existence of any bioprospecting activity. Any additional 
conditions would diminish the value of patents which would be detrimental 
to researched-based companies. Extending the patent process with 
subsequent rise in costs would, according to research by Wolfe and Zycher, 
lead to the estimated loss of 150-200 drugs over the next twenty years.51 
Excessive bureaucracy is stated as the main contributory cause for loss of 
new drugs.  
   The study recognizes the difficulty of comparing a regulatory and market-
based model. As the market-based model has not been widely adopted, it is 
a complicated task to compare the supposedly suppressed demand under a 
regulatory model with any conclusions of potential market demand in a 
                                                 
47 Bowen, Developing an effective international regime for access and benefit sharing for 
genetic resources; Using market-based instruments, the Australian APEC Study Centre, 
Monash University, Melbourne, December 2005. pp. 17-18. 
48 Ibid, p. 10. 
49 Ibid, p. 13. 
50 Ibid, p. 15. 
51 See Wolfe and Zycher, 2005, Biotechnological And Pharmaceutical Research And 
Development Investment Under a Patent-Based Access And Benefit-Sharing Regime, 
Pacific Research Institute for Public Policy, May 2005, where a patent-based regime is seen 
as an equivalent to a long-run tax on biotechnological and pharmaceutical research, thus 
having the effect of reducing investment into such research. 27 countries were subject to the 
study that was circulated in connection to a WIPO meeting in Geneva 6-10 June, 2005. 
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market-based model. The potential size of the bioprospecting market is not 
fully known.52  
   What standing indigenous communities have under the regulatory model 
contra the market-based model is also addressed. It is claimed that a 
regulatory regime makes the indigenous communities and their TK entirely 
dependent on government decisions. A market-based model could correct 
that situation through allocating assets, in the form of property rights to the 
indigenous communities. The advantage of transparency is also put 
forward.53
    
2.2 Biotechnology generations 
For the purpose of a more diversified understanding of the ABS issue and 
possible technology transfer in accordance with the TRIPs, an overview of 
the fundamental structure of the biotech industry and biotechnology is 
helpful.             
   Biotechnologies are often divided into three different generations. The 
first generation is not a novel craft but includes traditional technologies such 
as beer brewing and bread baking, technologies that have been utilized for 
thousands of years.54  The second generation begins with Louis Pasteur 
developing the process of fermentation of the antibiotics. It also includes 
tissue culture and modern plant and animal breeding.55 The “new 
biotechnologies” constitutes the third generation and is what one normally 
would define as biotechnology, i.e. genetic engineering techniques which 
transfer DNA from one life-form to another, creating transgenic organisms 
with new and useful properties.56 The PCR process, mentioned above,57 is 
included in the third generation of biotechnology.  
   Commercially attractive is the health area in which pharmaceutical 
companies provide the classic example with high returns and R&D intensive 
activity. Development is not only of new drugs but also diagnostics and 
enhancement of the efficiency of the drug discovery process.58
   The biotechnology “revolution”, i.e. mainly the third generation of 
biotechnologies has created new business opportunities and lead to the 
development of four types of business: 
 
• Technology providers who produce DNA sequencing machinery and 
other equipment; 
• Information providers who collect and organize sequencing 
information; 
• Research based companies, that are dedicated biotechnology firms, and 
generally do the upstream (i.e. initial or basic) research, but lack the 
                                                 
52 Bowen, APEC Study, supra f.n. 47, p. 21. 
53 Bowen, APEC-study, supra f.n. 47, p. 24. 
54 Dutfield, 2004, p.14. 
55 Ibid. 
56 Ibid. 
57 See page 5. 
58 Dutfield 2004, p.15. 
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resources or the intention to do downstream (i.e. final, close to the 
market) research, including product development and marketing; 
• Health, industrial and agricultural biotechnology firms. These are 
typically pharmaceutical, chemical and life science companies that are 
longer established businesses, but also larger dedicated biotechnology 
firms that are vertically integrated (performing on both upstream and 
downstream scale).59 
 
The process from basic research to a finished product is particularly long 
and costly within the pharmaceutical industry. Furthermore, one company 
may not be the best equipped to see through the whole process. This can 
also be an obstacle to bioprospecting and the regime of ABS. 
   Extensive patent portfolios are an important tool to attract investors which 
is crucial in research-based industry. Companies have a strong incentive to 
acquire patent with a broad scope and with claims that are drawn in a way 
that anticipates future scientific development. For developing countries, 
securing third generation IPRs to generate more wealth, the question 
remains on how to keep the value of basic biogenetic resources and to 
encourage technology transfer in line with the provisions in TRIPs. 
 
2.3 Bioprospecting economics in practice 
Companies, especially trans-national, operate on a global market. The 
financial risks that a company must bear in developing a new product are 
substantial and must be considered in the discussions around bioprospecting 
and ABS. IP protection over products and processes is the only way to 
recoup those investments. Under these circumstances, the value attributed to 
the raw biological resource and/or TK is dubious.60  
 
2.3.1 Successful(?) bioprospecting projects 
It is often said that the commercial use of bioprospecting is overrated and 
that there have yet to be any commercial products on the market emanating 
from such activities. The Merck-INBio agreement presented below which 
has been renewed a number of times has yet to bring forth any product. 
   However, there are examples of ethical bioprospecting, compliant to the 
CBD and with an ethical code that has been successful, generating royalties 
to the source providers. Such an example is Diversa Corporation (San 
Diego, California).  
   It can be difficult to evaluate the projects as they are presented and 
discussed in articles influenced by the different discourses presented above. 
How bioprospecting is approached in practice is nevertheless enlightening. 
 
                                                 
59 Dutfield, 2004, pp. 15-16. 
60 ten Kate and Laird, The commercial use of biodiversity: Access to genetic resources and 
benefit sharing, 2002, pp. 6-7.  
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2.3.1.1 The Merck-INBio Agreement 
A classic example often used is the agreement between Merck, a 
pharmaceutical company, and the National Biodiversity Institute 
(hereinafter INBio). INBio is a non-profit, non-governmental, scientific 
organization, created in 1989 on the recommendation of a presidential 
commission. It carries out bioprospecting activities through a formal 
agreement with the Ministry of Environment and Energy which is given ten 
percent of the research budget to cover costs of conservation. They also 
share the potential royalties on products deriving from Costa Rica, 
negotiated by INBio.61
   The first agreement between INBio and Merck was signed in 1991. Under 
the terms of the agreement, INBio would provide 10,000 samples of plants, 
animals, and soil to Merck. Merck would have the exclusive rights to study 
these samples for two years, and retain the patents to any drugs developed 
using the samples. In return, Merck paid INBio $1 million up front, and 
supplied the institute an additional $130,000 worth of laboratory equipment.        
   Interestingly, the deal included stipulations on royalties for any drugs 
developed from the biological samples provided. These royalties would be 
paid on all sales and not just sales in the United States or Costa Rica. As a 
part of the deal, half of these royalties will go to the Costa Rican Ministry of 
Environment and Energy, which would use the proceeds for conservation of 
biodiversity.62 The precise percentage amount of the royalties remained 
undisclosed for some time but was later disclosed to be 5 percent.63 The 
agreement has faced criticism, mainly due to the fact that it neither contains 
any provisions on indigenous knowledge, nor includes indigenous 
communities in the negotiations. It is the government and INBio that are 
beneficiaries to the Merck agreement, indigenous communities are not 
covered as INBio has stated no interest in TK.64 The agreements has 
furthermore been criticized for reducing INBio to ‘lab technicians’, however 
it is generally seen as a functional example of a bioprospecting agreement.  
 
2.3.1.2 Diversa Corporation 
This company has developed a model for ethical bioprospecting in which 
participating countries, institutions and corporate stakeholders benefit, all 
with minimal conflict and disagreement.65  
    Diversa Corporation is a biotech company concentrating on the 
discovery, evolution and production of commercially valuable enzymes and 
molecules with pharmaceutical, agricultural, chemical and industrial 
applications. Through its patented technologies it can rapidly target and 
                                                 
61 See INBio website: http://www.inbio.ac.cr/en/default.html, 12/04/06. 
62 Coughlin Jr, M. D, Using the Merck-INBio agreement to clarify the Convention on 
Biological Diversity, Columbia Journal of Transnational Law, 1993, Vol. 31 Iss. 2, pp. 337-
375. 
63 See http://www.grain.org/seedling/?id=372, 12/04/06. 
64 Dutfield, Between a rock and a hard place: Indigenous peoples, nationstates and the 
multinationals, 1998, in FAO document Medicinal plants for conservation and health care. 
65 Christoffersen and Mathur, Bioprospecting ethics & benefits; A model for effective 
benefit-sharing, Industrial Biotechnology, 2005, vol. 1,  No. 4,  p. 255. 
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identify substances from small environmental samples to discover novel 
gene products. It has entered into agreements in places such as Alaska, 
Antarctica, and Costa Rica, Ghana, Kenya, Russia and more.  
   The company has formed alliances and joint ventures with several larger 
companies such as GSK66 plc, Dow Chemical Company and affiliates with 
Syngenta AG.67
    Diversa has developed a set of principles for selecting partners and for 
creating agreements ensuring long-term relationships based on the 
principles of CBD, i.e. the sustainable use of genetic resources. The first 
step is to assess the country in question in terms of legal framework, 
political will, potential partners and the presence of unique habitats. When 
the country of interest and the institutional candidate have been identified, 
Diversa employs a bioprospecting framework, developed by the company, 
to help the structuring of the collaboration agreement.68
   Partners to Diversa have been receiving financial payment, third party 
grants and training of scientists. Infrastructural and scientific capacities 
improvements have also been made. 
   The model does not incorporate TK first-hand as the company focuses on 
micro-organisms as opposed to plant extracts. However, the potential 
conflict between traditional land tenure and property rights to genetic 
resources and moreover, ownership of the results from use of genetic 
resources is considered on a case-by-case basis in the access agreement and 
in the choice of benefit-sharing mechanisms employed.69
   There are three main criteria that Diversa considers central for successful 
bioprospecting programs. These are: 
 
• Efficient and reasonable permit systems (requiring no more than 
three months to secure a permit and oblige the permit holder to 
reasonable reporting criteria); 
• Efficient and reasonable benefit-sharing negotiations; and 
• A goal of creating fair and trusting relationships that result in 
expanded, long-term cooperation 
 
The company is of the opinion that “biodiversity collaborators” (often the 
source country) that are more flexible in terms of monetary benefit-sharing 
mechanisms are more able to capture the most value of biodiversity. As the 
market potential for an end-product usually is non-obvious, there is a 
possibility of using graduated royalties, depending on e.g. sales volumes of 
the end-product.70  
    
 
 
                                                 
66 GlaxoSmithKline. 
67 See corporate website: www.diversa.com, 06/04/06. 
68 Mathur et al., An overview of bioprospecting and the Diversa Model, IP Strategy Today, 
2004, No. 11, p. 2. 
69 Ibid, p. 7. 
70 Ibid, p. 15. 
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3 Bioprospecting and 
Intellectual Property Rights 
In this and the following chapter, the legislative provisions related to 
intellectual property, biological resources, traditional knowledge and access 
and benefit sharing are explored. It provides in no way an exhaustive 
overview of the international legal instruments in focus, rather, it isaimed to 
serve as a background to the issues around bioprospecting dealt with here 
and to provide a framework for comparison with the national and regional 
legislation scrutinized in chapter 5. 
 
3.1 Patent protection for inventions 
Before penetrating the issues surrounding patent protection on biological 
material with an indicated pharmaceutical use there are standard criteria that 
need to be fulfilled in order for the material/invention to receive patent 
protection. The patent itself is further defined in different structures so as to 
provide sufficient clarity. This is briefly explained below. 
3.1.1 Patentability criteria for patents 
There are three criteria to be fulfilled in order for an invention to be 
available for patent protection. These are novelty, inventive step and 
industrial application.71 TK in particular could have an impact for the 
assessment of at least two, i.e. novelty and inventive step. 
   The criteria of novelty (or new) is defined as that which is not part of the 
state of the art (often referred to as prior art). Prior art is in turn defined 
differently in the US72 than in Europe. In Europe it is defined in an 
unlimited sense, without territorial boundaries. Article 54(2) of the 
European Patent Convention (EPC) defines it as “everything made available 
to the public by means of a written or oral description, by use, or in any 
other way”. 
   The patent claim must contain at least one indispensable technical feature 
not found in the prior art. This is not necessarily linked to one specific 
document but if that document refers explicitly to another document (e.g. a 
document providing more details), the latter can be regarded as incorporated 
into the primary document.73  
   Inventive step, or non-obviousness, means that, with regard to prior art, it 
is not “obvious” to a person skilled in the art. This provision is commonly 
considered to be the most difficult criteria to apply in patent law, and it is 
equally difficult to analyse.74 This is particularly so within the 
                                                 
71 Article 27 TRIPs. 
72 Only written descriptions are accepted. See 35 U.S.C. § 102 (a)-(b).  
73 Domeij, Pharmaceutical Patents in Europe, 2000, p. 130. 
74 Ibid, p. 199. 
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pharmaceutical industry, due to the unpredictability of biological reactions. 
The term “obvious” is interpreted as not going beyond the normal progress 
of technology, but merely plainly or logically following from the prior art.75  
    The industrial applicability (usefulness) criteria is to make sure that 
patents are only permitted where the applicant has demonstrated that he can 
develop the commercial products that fall within the granted protection.76 A 
patent’s function is not to enable claims to what others may develop in the 
future.77  This could be relevant for bioprospecting when biological material 
is the subject of a patent application in the early stages of the research. Does 
the supposed area of utility, often indicated by the TK, fulfil the standards of 
industrial applicability? 
 
3.1.2 Patents on biological material 
Compounds with a therapeutic effect can be defined in three different ways 
or with a combination of these three different ways in order to provide 
sufficient clarity: structural formula, product-by-process claims and 
parameters relating to the compound.78   
   The Structural formula is the most precise way of defining a chemical 
compound and ought to be used if feasible. This normally is a delineated 
generalised structural formula, which forms the independent and broadest 
claim as the scope depends on which compounds may be created by 
combining the different alternatives mentioned for the different positions in 
the formula. Usually, dependent claims with a narrower scope are also 
applied for as a “safety measure”. In these dependent claims the 
commercially most interesting individual compounds are singled out, which 
prevents competitors to make selection inventions within the scope of the 
broader claim.79
   If the compound cannot be defined by any other means, the product-by-
process claim can be used. It is a definition of the compound by describing 
how it is manufactured. This type of claim is common where compounds are 
particularly susceptible to structural variations such as naturally occurring 
chemical compounds, catalysts (enzymes), macromolecules and products of 
microbiological process. The compounds are difficult to define 
unambiguously by their structure.80  
   However, the product-by-process claims are definitions of new 
compounds and the compound in itself must fulfil all patentability 
requirements. The manufacturing process itself can only serve as a 
                                                 
75 EPO Guidelines for examiners, Part C, Chapter IV, para. 9.4. The EPO has adopted the 
“problem and solution approach” for determining the inventive step criteria, which is to 
ensure an objective assessment and avoid an ex post facto analysis of the prior art. See EPO 
Guidelines, art C, Chapter IV, para. 9.8 and forward.  
76 Domeij, 2000, p. 28. 
77 Ibid. 
78 EPO Guidelines for examiners, Part C, Chapter III, para. 4.7a. 
79 Domeij, 2000, p. 68. 
80 Ibid. 
 24
definition, it cannot, however novel it might be, actually constitute the 
invention.81  
   Parameters relating to the claims; meaning characteristic aspects of a 
product, relating to characteristic features of the compound are sometimes 
used together with product-by-process claims. This is to get the most 
unambiguous scope of protection when a structural formula is not available. 
From the inventor’s standing, the scope of the claim should be as broad as 
possible, as there is a direct correlation between the breadth and the 
economic value of the patent.82
   Despite the spirit of patent laws requiring novelty, inventive step, and 
industrial application, biogenetic resources today may be considered closer 
to human "inventions" than to natural "discoveries" in legal terms. Thus, 
bioprospectors are able to reap profits from living organisms (or products 
derived therefrom) that would have been considered "common goods" only 
a century ago. The legislative response is, of course, attuned to the higher 
stakes in the current biogenetic resources market, but it might overlook the 
fact that these resources did not entirely originate in the laboratory.83
  
3.2 The TRIPs Agreement 
As a result of the Uruguay Round in 1995 of trade negotiation, a new 
intergovernmental organization was established. This was the World Trade 
Organization (WTO). Together with Japan and the EC, the US pressed for 
the inclusion of IPRs. The outcome was TRIPs, the Agreement on Trade-
related Aspects of Industrial Property Rights. The developed countries, 
spurred by strong industry lobbying, sought to establish a standardized IPR 
system with minimum standards that more closely reflected the IPR systems 
of the developed world. The existence of a dispute settlement mechanism 
within WTO (lacking from WIPO) also made it an attractive arena for an 
IPR agreement.   
 
3.2.1 Objectives and general principles 
Article 7 in TRIPs acknowledges the public policies of the agreement. It can 
be seen as part of the deal the developing countries got for accepting the 
TRIPs Agreement. It provides: 
 
The protection and enforcement of intellectual property rights should 
contribute to the promotion of technological innovation and to the transfer 
and dissemination of technology, to the mutual advantage of producers and 
                                                 
81 Ibid, p. 69. 
82 Domeij, 2000, p. 63. 
83 Environmental Policy Studies Workshop, School of International and Public Affairs, 
Columbia University, Access to Genetic Resources: An Evaluation of the Development and 
Implementation of Recent Regulation and Access Agreements, 1999, p. 6. 
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users of technological knowledge and in a manner conducive to social and 
economic welfare, and to a balance of rights and obligations. 
 
However, the main object with WTO and subsequently the TRIPs 
Agreement can be found in the preamble of the Agreement, namely: 
 
Members, 
Desiring to reduce distortions and impediments to international trade, and 
taking into account the need to promote effective and adequate protection of 
intellectual property rights, and to ensure that measures and procedures to 
enforce intellectual property rights do not themselves become barriers to 
legitimate trade. 
 
It also explicitly recognizes that Intellectual Property Rights are private 
rights. 
   In Article 3 one of the core principles of the Agreement is enshrined, 
namely that of national treatment. Simply put the principle purports that 
member states must award the same level of IP protection to nationals of 
other member states as they award their own nationals. This together with 
the next core principle in Article 4 and the standardization of IPR legislation 
can be said to constitute the heart of the Agreement. 
   Article 4 requires most-favoured-nation treatment of the member states. 
The concept means that any privileges, favours, advantages or immunities 
granted to one member state, immediately shall be accorded to the other 
member states of the Agreement.  
   The Agreement required all member states to have implemented these 
articles within on year of the entry into force of the WTO Agreement. 
 
3.2.2 The relevant articles 
Section 5 of the TRIPs Agreement deals with patents. Article 27, the first 
paragraph of the section is controversial, providing an indirect link to the 
CBD. 
   The relevant parts of the article state: 
 
1. Subject to the provisions of paragraphs 2 and 3, patents 
shall be available for any inventions, whether products or processes, in all 
fields of technology, provided that they are new, involve an inventive step 
and are capable of industrial application… 
 
2.   Members may exclude from patentability inventions, the prevention 
within their territory of the commercial exploitation of which is necessary to 
protect ordre public or morality, including to protect human, animal or 
plant life or health or to avoid serious prejudice to the environment, 
provided that such exclusion is not made merely because the exploitation is 
prohibited by their law. 
 
3.   Members may also exclude from patentability… 
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(b) plants and animals other than micro-organisms, and 
essentially biological processes for the production of plants or 
animals other than non-biological and microbiological 
processes. However, Members shall provide for the protection 
of plant varieties either by patents or by an effective sui 
generis system or by any combination thereof. The provisions 
of this subparagraph shall be reviewed four years after the 
date of entry into force of the WTO Agreement. 
 
3.2.2.1 Article 27.1 
This is a significant Article for several reasons. Firstly it defines patentable 
subject-matter. The conditional criteria are novelty, inventive step and 
industrial application.  
   In case a Member chooses to protect living organisms through patents, 
only such organisms having undergone a certain technical modification are 
not pre-existent in nature and may thus be considered as new. Since the 
determination of the precise meaning of novelty (like the other patentability 
criteria) is left to the WTO Members’ discretion, the degree of technical 
intervention required to satisfy the novelty criterion varies widely among 
domestic patent laws.84
   Secondly, it stipulates non-discrimination in three different areas. In the 
first area it requires that patents be available and patent rights enjoyable 
without discrimination as to the place of invention. This had significant 
consequences for the USA who had to change its patent law. The US has 
the, now unique, system of first-to-invent as opposed to first-to-file which 
operates everywhere else in the world. Up until the TRIPs Agreement, US 
courts were barred from accepting foreign85 evidence of dates of the 
invention in cases where priority of invention was to be established.86  
   The second area of non-discrimination relates to all fields of technology. 
Several countries at that time did not provide patent production for 
pharmaceutical products and/or processes and the introduction this 
amounted to an important advancement for the pharmaceutical industry.87     
   The third and last area of non-discrimination refers to the words whether 
products are imported or locally produced. Another common requirement 
was that patented products had to be manufactured locally in order to enjoy 
IP protection. Now a product can be imported and put on the market without 
loosing national IP protection.88
                                                 
84 UNCTAD-ICTSD, 2005, Resource Book on TRIPS and Development, pp. 389-390. 
85 Section 104 of the US Patent Act stated that ’in proceedings in the Patent and Trademark 
Office, in the courts, and before any other competent authority, an applicant for a patent, or 
a patentee, may not establish a date of invention by reference to knowledge or use thereof, 
or any other activity with respect thereto, in a foreign country…’. This was subsequently 
changed in 1994 and the phrase ‘other than a NAFTA country or a WTO member country’ 
was added.  
86 Dinwoodie et al, International Intellectual Property and Policy, 2001, p. 389. 
87 Dutfield, Intellectual Property, Biogenetic Resources and Traditional Knowledge, 2004, 
p. 27. 
88 Ibid.  
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 3.2.2.2 Article 27.2 
Article 27.2 may at first seem to provide for exceptions common in 
international law, namely ordre public and morality. 
   The term ordre public, derived from French law, is not an easy term to 
translate into English. The English term public order is more narrowly 
construed, making the French concept more akin to the term public policy. 
In short it relates to matters that threaten the structure of civil society as 
such.89 Protection of human, animal or plant life, health or serious prejudice 
to the environment is stated as legitimate reasons. The Article does put such 
possibilities under one important condition; it may only be invoked if the 
commercial exploitation needs to be prevented to protect the interests above. 
It precludes commercial exploitation as such and cannot be used when there 
is an interest in e.g. public health for the diffusion of the invention. In other 
words, invoking ordre public or morality means no commercialization at 
all.90 However, prohibition on exploitation of the invention is not a reason 
to refuse patentability. 
   How large is the countries’ discretional scope in this matter? It has been 
argued that the exclusions provided in 27.2 should be narrowly applied, on a 
case-by-case basis in order for member countries to comply with TRIPs. If 
the TRIPs Agreement intended for broad clauses of patents (e.g. life-forms) 
to be allowed to be excluded, it would have been explicitly indicated.91 
Nevertheless, some countries have included such an exception, e.g. the 
French Patent Law, as amended 1994. It reads as follows: 
 
…The human body, its elements and products as well as the 
knowledge of the whole or part of a human gene cannot as 
such be subject to patents...92
 
The European Patent Office (EPO) has on the other hand routinely granted 
patents on human genes or cell lines and the Opposition Division of the 
EPO has not found the patenting of human genes as inherently unethical.93
 
3.2.2.3 Article 27.3 (b) 
Often called the biotechnology-clause, Article 27.3(b) is the only article in 
the Agreement to be explicitly subject to an early review. The debate 
surrounding it has revealed different, seemingly irreconcilable, viewpoints 
(see further below), starting with the dispute over the term review. 
                                                 
89 UNCTAD-ICTSD, 2005, Resource Book on TRIPS and Development, p. 375. 
90 Ibid, p. 376. 
91 Moufang, The Concept of ‘ordre public’ and Morality in Patent Law, 1998, pp. 65-77.  
92 Book VI, Title I, Chapter 1, Section 3, Art. L. 611-17 (a), Code De La Propriete 
Intellectuelle. 
93 See e.g. http://www.european-patent-office.org/news/pressrel/2005_10_27_e.htm, 
03/04/06 or 
http://www.ladas.com/BULLETINS/1995/1195Bulletin/EPO_PatentsHumanGenes.html, 
03/04/06. 
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Developed countries, e.g. the US and Australia94, held that the Article called 
for a review of implementation while for developing countries, “review” 
should enable the revising of the Article itself.95 With the Doha-declaration 
in 2001, a discussion on review, the relationship with the CBD and 
protection of TK was initiated.  
   The Article allows for plants and animals other than micro-organisms, and 
essentially biological processes for the production of plants and animals 
other than non-biological and microbiological processes, to be excluded 
from patentability. Plant variety protection is introduced as a compulsory 
requirement.96 A key area of uncertainty is how the term micro-organism 
should be defined. In the US the concept of ‘new’ does not mean pre-
existing, but novel in relation to prior art. Hence, a purified or isolated 
natural product would be patentable. The EU has adopted a similar approach 
with the Directive on Biotechnological Inventions97 (hereinafter 
Biotechnology Directive). The EPO Guidelines for examiners provide some 
clarity to how the term is to be interpreted:  
 
The term "micro-organism" includes bacteria and other 
generally unicellular organisms with dimensions beneath the limits of vision 
which can be propagated and manipulated in a laboratory,… including 
plasmids and viruses and unicellular fungi (including yeasts)98
 
The term microbiological process is defined as well for the purposes of 
determining what an essentially biological process is. The Guidelines 
explain it as ‘any process involving or performed upon or resulting in 
microbiological material.’ It covers not only processes performed upon 
microbiological material or resulting in such (e.g. by genetic engineering), 
but processes including both microbiological and non-microbiological steps 
can be claimed.99
   The product of a microbiological process may also be patentable through 
product claim. For the purposes of Article 53(b)100, the dissemination of the 
micro-organism itself is to be construed as a microbiological process. 
Consequently, as a product obtained by a microbiological process, the 
micro-organism can be protected per se.101
   The key to interpreting the difference between a mere discovery and an 
actual invention (the line can with microbiological inventions be rather 
blurred), is the technical effect. An example would be a substance occurring 
in nature which is found to have an antibiotic effect. Additionally, a micro-
organism that is discovered to exist in nature and to produce an antibiotic, 
                                                 
94 See e.g. U.S. communication IP/C/W/209; Australia communication IP/C/W/310 (“the 
coverage of this agenda item is relatively narrow, that is, the item is concerned with a 
review of the effectiveness of the operation of an optional exclusion to patentability . . . ”). 
95 UNCTAD-ICTSD, 2005, supra f.n. 91, p. 395. 
96 E.g. the UPOV-regime.  
97 Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the 
legal protection of biotechnological inventions. [OJ 2/1999, 101]. 
98 EPO Guidelines for examiners, Part C, Chapter IV, para. 3.5.1.  
99 See also Article 2.2 Biotechnology Directive. 
100 Article 53(b) of the EPC on which Article 27.3(b) is modelled. 
101 EPO Guidelines for examiners, Part C, Chapter IV, para. 3.5.1. 
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the micro-organism as such may be patentable as an aspect of the 
invention.102 Technical effect or process is also used as the defining criteria 
in the preamble to the Biotechnology Directive.103 Thus, the ambit between 
essentially biological processes contra non-biological and microbiological 
processes appears to offer considerable room for interpretation. 
 
3.2.3 Protection of undisclosed information 
Article 39 provides for the protection of undisclosed information, more 
generally referred to as “trade-secrets” or “know-how”. Although not 
usually considered an IPR, it was proposed by the US, the EU, and 
Switzerland as a necessary measure for the fulfilment of the obligation 
under the Paris Convention to suppress unfair competition.104 The 
obligation under Article 39.1 is consequently limited to the protection 
against unfair competition, not of exploitation per se.  
   Unlike other IPRs the protection does not afford “exclusive right”. Falling 
under a category of intellectual property (TRIPs Article 1.2), it does not 
imply any existence of “property rights” in the undisclosed information. 
Instead there is recognition of the “possession” or de facto “control” over 
the said information.   
   Undisclosed information encompasses any secret information of 
commercial value such as; 
 
• technical know-how, such as design, process, formula and other 
technological knowledge often resulting from experience and 
intellectual ability; 
• data of commercial value, such as marketing plans, customers lists and 
other business-related information that provides an advantage over 
competitors; 
• test and other data submitted for the approval of pharmaceutical and 
chemical products for agriculture.105 
 
Protection is to be provided against the disclosure, acquisition or utilization 
without consent in “a manner contrary to honest commercial practices” as 
long as the information a) is secret, i.e. not generally known or readily 
accessible to persons that normally deal with the kind of information in 
question; b) has commercial value because of its secrecy and c) has been 
subject to reasonable steps to be kept secret.106 The commercial value must 
have actual value under the Agreement but it is possible for member 
countries to extend the protection for potential value as well.107
   For the purpose of this provision, “a manner contrary to honest 
commercial practices” stands for, at least, practices such as breach of 
                                                 
102 Ibid, para. 2.3.1.  
103 Biotechnology Directive, preamble para. 20-21. 
104 Paris Convention for the Protection of Industrial Property, 20 March 1883, Article 10bis. 
105 UNCTAD-ICTSD, 2005, Resource Book on TRIPS and Development, p. 521. 
106 TRIPs, Article 39.2 (a)-(c). 
107 UNCTAD-ICTSD, 2005, p. 529. 
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contract, breach of confidence and inducement to breach, and includes the 
acquisition of undisclosed information by third parties who knew, or were 
grossly negligent in failing to know, that such practices were involved in the 
acquisition.108
 
                                                 
108 TRIPs, footnote to Article 39. 
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4 The Convention on Biological 
Diversity 
The main international legal instruments concerning biodiversity in general 
and the issues of ABS and TK in conjunction with bioprospecting in 
particular, is the Convention on Biodiversity.   
The CBD was the result of the Earth Summit in Rio de Janeiro, Brazil, in 
1992. It entered into force on 29 December 1993.109 Presently 188 countries 
are parties to the Convention. All the Member States of the European Union 
are parties however the USA most notably, is not.110  
  
4.1 General overview 
The CBD is a comprehensive legal instrument but as an United Nations 
effort, it also suffers from the disadvantages of international agreements, 
namely lack of enforcement mechanisms and dependence on national 
implementation. It creates a body of rules on in situ and ex situ111 
conservation and establishes procedural requirements such as the 
elaboration of national biodiversity strategies.112  It also constitutes an 
institutional framework for the continual work on legal, policy and scientific 
initiatives on biological diversity.113 The Parties to the Convention are 
obliged to take a number of measures including monitoring and 
identification of biodiversity, environmental impact assessments, 
developing national strategies and to integrate the biodiversity policy into 
the relevant sectoral and and cross-sectoral plans, policies and 
programmes.114
 
4.1.1 Who is bound by the Convention 
The CBD, as an international Treaty establishes rights and obligations of its 
Contacting Parties, the sovereign states. Private individuals do not have to 
adhere to the Convention. There are however, institutions which are 
governmental bodies of the Contracting Parties that arguably could be 
                                                 
109 Bernstein et al, Earth Negotiations Bulletin, 1993, available at: 
http://www.iisd.ca/vol09/0918001e.html, 26-01-2006. 
110 http://www.biodiv.org/world/parties.asp, 26-01-2006. 
111 in situ: Genetic resources existing within ecosystems and natural habitats. ex situ: 
components of biological diversity outside their natural habitats, CBD definitions. It 
encompasses conservation in botanical gardens, zoos and aquaria, genebanks and other 
collections. 
112 Tarasofsky, R, The Relationship Between the TRIPs Agreement and the Convention on 
Biological Diversity: Towards a Pragmatic Approach, RECIEL, 1997, Vol. 6, Iss. 2, p. 
149. 
113 ten Kate and Laird, 2002, p. 13.  
114 Ibid, p.14. 
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bound by the CBD provisions. Further, public institutions, e.g. universities, 
genebanks or botanic gardens may also be bound, depending on the 
provisions and to what extent they rely on public funding and grants that 
obligate adherence to public law. The obligation to comply with the CBD 
would then not be dependent on national implementation. 
 
4.2 Objectives and general principles 
The objectives of the Convention on Biological Diversity are enshrined in 
the Preamble and Article 1. The intrinsic value of and the importance of the 
conservation of biological diversity is affirmed. The close relationship and 
dependence of many indigenous and local communities embodying 
traditional lifestyles on biological resources is also recognized. In Article 1 
the objectives are stated as the conservation of biodiversity115, the 
sustainable us of its components and the fair and equitable sharing of the 
benefits arising out of the utilization of genetic resources. The objectives are 
in other words three, conservation, sustainable use and fair and equitable 
sharing of the benefits accrued. 
   The most important general principle is enshrined in Article 3. The 
principle of national sovereignty over their biological resources replaced 
the earlier notion that biological resources were  
 
“common heritage of mankind to be preserved and 
 freely available for use, for the benefit of present and future  
generations”.116  
 
That ideology was challenged in the 1980s due to a perceived imbalance 
between free access to genetic resources on the one hand and the 
development of patents on biotechnological inventions on the other. A 
strong environmental movement pushing to convince the public on issues 
such as the perceived value of biodiversity, especially to the pharmaceutical 
industry and the emerging life-science industry, and the more classical 
North-South political relationship.117
 
4.3 Relevant articles of the Convention 
The most significant Article with reference to TK is Article 8 (j). It states: 
 
Each Contracting Party shall, as far as possible and as 
appropriate: 
                                                 
115 Biological diversity and biodiversity are interchangeably used in this thesis. 
116 FAO Conference of November 1983 when adopting the International Undertaking (IU) 
on plant genetic resources. 
117 Le Buanec, Plant genetic resources and freedom to operate, Euphytica, 2005, Vol. 146, 
Iss. 1, p. 2. 
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Subject to its national legislation, respect, preserve and maintain 
knowledge, innovations and practices of indigenous and local communities 
embodying traditional lifestyles relevant for the conservation and 
sustainable use of biological diversity and promote their wider application 
with the approval and involvement of the holders of such knowledge, 
innovations and practices and encourage the equitable sharing of the 
benefits arising from the utilization of such knowledge, innovations and 
practices.  
 
The language of the article is somewhat vague and possible obligations 
arising from it are weakened by being preceded by term such as “as far as 
possible and as appropriate” and “subject to national legislation. In 2000 the 
Conference of the Parties to the Convention on Biological Diversity (COP) 
adopted a decision to clarify matters saying that access to TK should be 
subject to PIC of such holders of TK. Although a laudable effort the 
question is to what extent this serves to facilitate access to biological 
resources as it raises difficult practical and cultural issues.118
Article 16 deals with access to and transfer of technology. Transfer of 
technology, including biotechnology is essential for the objectives of the 
Convention and access shall be facilitated through legislative, administrative 
or policy measures. The transfer is to be made under mutually agreed terms 
and IPRs shall be adequately protected.119 State measures to facilitate 
private sector participation, e.g. joint R&D or transfer of technology, are 
also to be undertaken.  
   In Article 16(5) the CBD’s relationship with patents and other intellectual 
property rights is articulated: 
 
The Contracting Parties, recognizing that patents and other 
intellectual property rights may have an influence on the implementation of 
this Convention, shall cooperate in this regard subject to national 
legislation and international law in order to ensure that such rights are 
supportive and do not run counter to its objectives.   
 
This can be interpreted as a subtle hint that the objectives of the CBD are 
superior to intellectual property law and if there is inconsistency, an 
adjustment of IPR rules would be possible. 
   Article 19 specifically deals with the handling of biotechnology and the 
distribution of its benefits. It obligates the Contracting Parties to take 
legislative, administrative or policy measures to make available an effective 
participation in biotechnological research, especially by developing 
countries that provide the biological resources for such research. Measures 
shall be taken to promote and advance access to the results and benefits 
                                                 
118 Greene, 2002, ‘Intellectual Property, Resources or Territory? Reframing the Debate over 
Indigenous Rights, Traditional Knowledge, and Pharmaceutical Bioprospection’, in 
Bradley, M. P, and Petro, P (eds) Truth Claims: Representation and Human Rights, pp. 
229-249. 
119 Article 16(2). The term adequate and effective protection is specifically there to 
establish a link with the, then draft, TRIPs Agreement. It is however also stated in the last 
sentence that the application of this paragraph shall be consistent with paragraphs 3, 4 and 
5, i.e. Article 16(5).  
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arising from such research. Access shall be on a fair and equitable basis and 
on mutually agreed terms. 
 
4.3.1 Article 15, access to genetic resources 
In this article, several of the fundamental provisions are laid down.  Article 
15 (1) expresses the right of the sovereign States to determine access to their 
natural and genetic resources through national legislation, a reflection of the 
general sovereignty principle in Article 3. According to Article 15 (4), 
access when granted, shall be on mutually agreed terms. Any subsequent 
benefit-sharing shall comply with articles 16 and 19 and as well be mutually 
agreed upon (Article 15(7)). Parties must nevertheless in consistence with 
Article 15 (2) endeavour to facilitate access, i.e. striking a balance between 
controlling access in order to ensure that mutually agreed terms are reached, 
but make sure that procedures and requirements do not block access.120  
   The crucial concept of prior informed consent is enshrined in Article 15 
(5). It is not defined any closer in the Convention but there is substantial 
literature on the subject. The last phrase of article 15(5): “unless otherwise 
determined by that Party” means that imposing the requirement of prior 
informed consent is an option rather than an obligation, with the 
consequence that a user is only required to submit to PIC if the providing 
Party has taken steps to establish the necessary procedure in its legal 
system.121
     
4.3.1.1 Whose consent is required? 
Identifying which governmental authority from whom to obtain permission 
from can prove to be difficult. In countries where legal and administrative 
steps have been taken, the legislation often identifies the appropriate organ. 
However, many countries have not yet enacted such legislation making 
access to biological resources subject to a patchwork of different laws, e.g. 
access to protected areas, export, the CITES122, biosafety, laws on private 
property etcetera, and an equally diverse group of organizations such as 
ministries, local and regional governments, institutions and individuals.123  
   The question of whose consent that is required is further complicated. The 
CBD only provisions PIC at the national level, on the condition that national 
legislation stipulating PIC is enacted. Moreover it is necessary for the 
countries to enact laws with provisions of mandatory PIC of 
indigenous/local communities. This has been done in various ways as can be 
seen in the national examples below. 
                                                 
120 ten Kate and Laird, 2002, p. 27.  
121 Hendrickx, F, Koester, V, Prip, C, The Convention on Biological Diversity – Access to 
Genetic Resources: A legal Analyses, Environmental Policy and Law, 1993, Vol. 23, Iss. 6, 
p. 250. 
122 Convention on International Trade in Endangered Species of Wild Fauna and Flora. 
123 ten Kate and Laird, 2002, pp. 27-28. 
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PIC at local level involves the same disclosure requirements as above but in 
a form more suitable for the context. Posey and Dutfield have written about 
it as a process in which: 
 
• the person seeking access must obtain consent from every affected 
community in the traditionally recognized manner;  
• before seeking consent, the person seeking access should distribute and 
hold community discussions regarding all relevant information to the 
community in a culturally appropriate manner; 
• consent should be part of an ongoing process in which the community 
may choose to give or not to give consent; and  
• community leaders may revoke consent for legitimate reasons.124 
 
As noted above it does create uncertainty. How much must stakeholders 
understand in order to be able to give a truly informed consent? On what 
level do they need to be informed on issues such as patent laws, 
conservation biology, and biotechnology? It is nevertheless clear that PIC 
cannot be given in a single unitary moment of time at the beginning of the 
bioprospecting project, but it must be an ongoing process of interactive 
character that gradually expands to cover issues of a broader interest.125
   
4.3.2 The Bonn Guidelines 
The Bonn Guidelines were adopted at the 6th Conference of the Parties to 
the Convention (COP) in the Hague in April 2002. Although the Guidelines 
are voluntary126 they were adopted unanimously by 180 countries which 
give an undisputable authority.127 It was adopted to assist in adopting 
effective measures and strategies implementing the CBD. 
   The Guidelines identify the steps, with particular reference to Articles 8(j), 
10(c)128, 15, 16 and 19, in the access and benefit-sharing process, with an 
emphasis on the obligation for users to seek the prior informed consent of 
providers. They also provide the basic requirements for mutually agreed 
terms and define the main roles and responsibilities of users and providers 
as well as stress the importance of the involvement of all stakeholders. 
Finally, they enumerate suggested elements to be included in material 
transfer agreements and provide an indicative list of both monetary and non-
monetary benefits.129
  
                                                 
124 Posey and Dutfield, 1996. 
125 Berlin and Berlin, 2003, pp.630-631. 
126 CBD, Article 7. 
127 Secretariat of the Convention on Biological Diversity, 2002, Bonn Guidelines on Access 
to Genetic Resources and Fair and Equitable Sharing of the Benefits Arising out of their 
Utilization, Montreal: Secretariat of the Convention on Biological Diversity. 
128 Article 10(c) reads as follows: Each Contracting Party shall, as far as possible and as 
appropriate: Protect and encourage customary use of biological resources in accordance 
with traditional cultural practices that are compatible with conservation or sustainable use 
requirements.  
129 Ibid. 
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4.4 The Relationship between the TRIPs 
Agreement and the CBD 
The direct relationship between TRIPs and the CBD is an issue of debate. 
While two instruments with different objectives, there is no doubt that they 
intersect when dealing with the activities and results of bioprospecting, 
namely patenting of biological resources and associated TK, issues of 
technology transfer and the controversial issue of the patenting of life, and 
with the Doha Declaration from 2001, the relationship was brought into 
WTO discussions. 
   Although, the connection between the two international documents is 
frequently made, the exact nature of this connection is still a topic of 
considerable rhetoric and political controversy.130 The TRIPs Agreement 
has the focus on establishing harmonized global IPR regime and technology 
transfer and the CBD concerns the conservation and sustainable use of 
biodiversity. The philosophical point of departure in TRIPs is the 
fundamental belief in the need for adequate (strong) private property rights 
within the framework of a market economy. Typically it is the developed 
countries that are better placed to carry out R&D leading to innovation in 
need of IP protection and thus enjoying the benefits of IPRs. 
   The Biodiversity Convention sets out from a different starting-point. 
Although recognizing the potential influence of IPRs on the implementation 
of the Convention such rights, they must not run counter to its objectives.131  
   There is no direct relation between IPRs and conservation of biodiversity, 
nevertheless, IPRs form part of the economic and social context in which 
conservation takes place. Intellectual property rights are relevant for the 
crafting of ABS arrangements relating to equity. They can enhance or hinder 
the equitable economic benefit sharing to the custodians of biodiversity 
arising from the conservation and sustainable use of biological resources.  
   A relevant question to be asked is to what extent they facilitate access to 
and transfer of environmentally-sound technology. Another general issue is 
the much-debated question of whether life forms should be patentable to the 
extent of falling under the CBD requirement to regulate processes and 
activities harmful to biological diversity.132     
   The relationship between TRIPs Article 27.3(b), CBD and TK has also 
been explored within the WTO. Discussions on the relationship have been 
taking place in the TRIPs Council since 1999. 
   Article 27.3(b) allows exclusions from patentability but does not provide 
for any clear definitions of the key terms (see above). Some countries have 
requested that the TRIPs Council should closer examine and clarify those 
terms in order to make the scope of the exclusion possibility more clear. It 
has not been a suggestion free of opposition.  
                                                 
130 Tarasofsky, R, The Relationship Between the TRIPs Agreement and the Convention on 
Biological Diversity: Towards a Pragmatic Approach, RECIEL, 1997, Vol. 6, Iss. 2, p. 
148. 
131 Article 16 (5) CBD. 
132 Tarasofsky, 1997, p. 149. 
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As the current IPR system stems from the continuing process to encourage 
trade and technological development, it has gradually expanded, recognizing 
new rights and new patentable subject-matters. Now it is the legitimacy of 
the whole system that is in dispute while questions on compulsory 
disclosure of origin still remain controversial.133 There have been a number 
of submissions to the TRIPs Council where mainly four different views can 
be delineated: 
 
• there is no conflict between the Agreements and governments can 
implement the two in a mutually supportive way through national 
measures; 
• there is no conflict between the Agreements and while governments can 
implement the two in a mutually supportive way through national 
measures, further study is required to determine whether any 
international action in relation to the patent system is called for; 
• there is no inherent conflict between the two Agreements but there is a 
case for international action in relation to the patent system in order to 
ensure or enhance, in their implementation, the mutual supportiveness 
of both Agreements. There are differences of view on the exact nature 
of the international action needed, including on whether or not an 
amendment is needed to the TRIPS Agreement, to promote the 
objectives of the CBD; 
• there is inherent conflict between the two instruments, and the TRIPS 
Agreement needs to be amended to remove such conflict.134 
 
4.4.1 Developed v. developing states 
Despite the fact that it is often held that indigenous groups wish to keep 
their TK outside the conventional patent system on the grounds that a 
system based on time-limited individual exclusive rights is inherently 
incompatible with the nature of TK, many developing countries are 
expressing a different view in the discussions of the TRIPs Council. 
Developing countries maintain that the issue of misappropriation of 
biological resources and associated TK together with ABS must be 
recognized within the current IPR system in the form of disclosure 
requirements in patent applications. As mentioned above, clearer definitions 
of key terms such as microbiological processes, to give a more precise scope 
of TRIPs Article 27.3 (b) has been requested by several developing 
countries  
   The EC does not find the TRIPs Council to be an appropriate forum but 
would rather refer the issue of closer definition of key terms to WIPO, 
which has the competence to deal with complex technicalities such as this 
one. furthermore, the EC argues that closer definitions of the terms would 
limit the flexibility that the member states now enjoy.135 An amendment to 
                                                 
133 Communication from Peru, IP/C/W/441/Rev.1, 19 May 2005, p.2. 
134 Note by the Secretariat, IP/C/W/368/Rev.1, 8 February 2006, p. 4. 
135 Communication from the EC, IP/C/W/383, 17 October 2002, p. 6. 
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Article 27.3 (b) would, to use a metaphor, open up a can of worms and 
could lead to demands for broader protection of biotechnological inventions. 
Therefore, the EC is of the opinion that the current balance struck is apt and 
should not be amended. In the WTO Communication from the EC it is also 
reminded that IPRs for biotech inventions are key factors for the domestic 
development of skills in that sector.136
Developed countries, the USA and Japan in particular has fiercely opposed 
adding disclosure of origin as a compulsory requirement for patent 
applications, stating that the matter is better pursued through the work in 
WIPO’s Intergovernmental Committee on Intellectual  Property and Genetic 
Resources, Traditional Knowledge and Folklore (IGC). Switzerland has 
acknowledged that such issues should be addressed under the patent system 
and has proposed an amendment to the WIPO Patent Cooperation Treaty 
(PCT) where, in appropriate cases, disclosure of origin of the genetic 
material would be a voluntary requirement.137 The EC on the other hand has 
approved of the idea of a system to keep track of all patent applications 
concerning genetic resources but has clarified that the legal consequences 
for non-respect of disclosure of origin should lie outside the scope of patent 
law.138  
   The United States has consistently held the opinion that patent law is not 
designed to regulate general misconduct or misappropriation of biogenetic 
resources, but that the establishment of searchable organized databases, the 
disclosure of information material to patentability and the post-grant 
opposition and possible re-examination procedure, directly achieves this 
goal.139 The US regards new patent disclosure requirements within the 
TRIPs as an inappropriate solution,140 and recalls that the CBD contains no 
obligation or mentioning of patent disclosure requirement.141 The US states 
that such a requirement would only provide a useless “hint”, with little or no 
effect of protecting the intellectual contribution in question.142 Instead, a 
contract-based system is proposed as it is seen as the best way to maintain 
control of the biological resource and its associated TK. Contracts could 
contain regular reporting requirements, choice of law clauses and provisions 
on PIC and source of origin for patent applications.143   
       
4.4.2 Digital libraries as protection for TK 
When discussing traditional knowledge it is useful to work around three 
operational objectives. These are: to preserve TK; to protect TK; and to 
promote TK. These objectives are interlinked and need to be considered 
together. If one only looked at an issue from one perspective it can be 
                                                 
136 Communication from the EC, IP/C/W/383, 17 October 2002, p, 7. 
137 IP/C/W/400; reiterated in IP/C/W/423. 
138 See EC Communication from 17 October 2002, IP/C/W/383. 
139 Communication of the United States, IP/C/W/469, 13 March 2006, p. 2. 
140 Ibid, p. 3. 
141 Communication of the United States, IP/C/W/449, 10 June 2005, p. 2.  
142 IP/C/W/469, 13 March 2006, e.g. pp. 6 and 7. 
143 IP/C/W/469, 13 March 2006, para. 36 and IP/C/W/434,26 November, 2004, para. 20. 
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counterproductive from another. An example is TK documentation, which 
often is put forward as a mean for Patent Offices around the world to 
establish prior art, can also facilitate unauthorized commercialization if not 
the objective of protection also is considered.144  
Another issue is the deeply personal character of TK. It cannot be separated 
from the communities and their customs. TK is a living body of knowledge 
that really only can be preserved and protected if the communities’ 
economic and cultural integrity is protected. TK stored in a database does 
not provide information to the full extent, as would a traditional holder of 
TK.145 As an integral part of the life of the community it is linked to 
questions such as territorial rights, rights over and to resources and human 
rights.  
   The establishing of TK Digital Libraries constitutes a defensive cause of 
action for protecting TK. Defensive tactics is mainly to prevent the 
misappropriation or misuse of TK, i.e. the granting of “bad patents”, patents 
based on TK to unauthorized third parties. 
  Further defensive action is to make the Digital Libraries available to patent 
examiners across the world and, perhaps most important, the legal 
requirement to disclose the source of origin of the biological resource and 
the related TK. However, none of the developed countries, the US, EU and 
Japan incorporate any conditions for disclosure for granting patents. 
 
4.5 Non-legislative documents 
Several guidelines have been adopted through various collaborations. These 
are normally voluntary and serve to provide a framework for ‘best practice’ 
and to ensure good faith between parties in bioprospecting activities. Three 
different examples are presented below.    
  
4.5.1 The FAO International Code of Conduct  
The FAO146 International Code of Conduct for Plant Germplasm Collecting 
and Transfer was adopted as early as 1993. The 1990s was furthermore the 
time when the “biopiracy” debate intensified. It should be seen as a 
balancing act and a promoter of rational collection and sustainable use of 
genetic resources. The Code aspires to prevent genetic erosion and to protect 
the interests of both donors and collectors of germplasm. The Code is 
                                                 
144 Report of the UNCTAD-Commonwealth Secretariat Workshop on Elements of National 
Sui Generis Systems for the Preservation, Protection, and Promotion of Traditional 
Knowledge, Innovations and Practices and Options for an International Framework Geneva 
February 4-6 2004, Unedited Version, p. 3.  
145 Supra f.n.145, p. 7. 
146 The Food and Agriculture Organization of the United Nations is one of the largest 
specialized agencies within the UN system. FAO was founded in 1945 with the mandate to 
raise levels of nutrition and standards of living, to improve agricultural productivity and to 
improve the condition of rural populations. There are 183 Member States and one member 
organization, the EU. 
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voluntary and primarily directed to governments however; it also provides 
guidelines for collectors.147 Chapter IV and V establishes the 
responsibilities of the collectors (bioprospectors), sponsors, curators and 
users. The responsibilities entail, inter alia, to upon arrival in the host 
country acquaint themselves with relevant research results148, respect local 
customs and demonstrate a sense of gratitude towards local communities, 
especially if TK is being used on the characteristics and value of the 
resource149, and to inform the host country on impending threats to plant 
population.150    
   Sponsors should make sure that the Code is observed and curators should 
as far as possible respond to enquiries from local communities and the host-
country. They should also upon request supply samples of the 
germplasm.151  
 
4.5.2 MOSAICC  
The Micro-Organisms Sustainable Use and Access Regulation, International 
Code of Conduct, was adopted in 2000. MOSAICC is the result of a 
consensus obtained between a balanced group of representatives from North 
and South, including representatives from the public (government, culture 
collections, academics, NGOs) and the private sector (pharmaceutical, 
chemical and food industry).152 It is a voluntary document, aimed at 
assisting microbiologists who want to access biological material and 
countries who wish to establish mechanisms for PIC and to monitor transfer 
of material through material transfer agreements (MTAs).  
   PIC is narrowly and literally interpreted as the prior informed consent of 
the country (or designated national competent authority) providing the 
biological resource. It refers to Article 15 of the CBD which confirms 
countries sovereign rights to their biological resources (see above). 
MOSAICC recommends that permission should be obtained from the 
landowner where necessary; it does however not refer to TK or PIC from 
indigenous/local communities. It is for national legislation to create 
mechanisms for PIC other than the narrow CBD concept.         
   The Code of Conduct nevertheless recommends that indigenous 
communities are included as partners to an agreement in so far as the 
community is the owner/usufructuary of the area where the biological 
resource is collected; is well represented by an officially recognized 
representative and; willing to preserve and maintain knowledge, innovations 
and practices relevant for the conservation and sustainable use of the 
resource.153
                                                 
147 International Code Of Conduct For Plant Germplasm Collecting And Transfer, FAO 
Conference, 27th session, November 1993, Preamble and Articles 3.1 and 3.3. 
148 Ibid, Article 9.1.  
149 Ibid, Article 10.1. 
150 Ibid, Article 11.1 (e). 
151 Ibid, Articles 12.1 and 13.2.  
152 MOSAICC, p. 4, footnote 2. 
153 MOSAICC, Section I.6, p. 14. 
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   MTAs are defined as a generic term which can cover everything from very 
short documents such as shipment documents, delivery notice, invoices 
containing standard requirements or more detailed contracts including 
mutually agreed terms. The Code of Conduct sets minimum requirements 
for a document to be defined as a MTA. These are: 
 
• information about the in-situ origin; 
• information about provider and recipient; 
• mutually agreed terms for the access to and the transfer of microbial 
genetic resources (MGRs), the access to and the transfer of technology, 
the fair and equitable sharing of the benefits as well as for technical 
and scientific cooperation. 
 
The main advantage of the MOSAICC is the MTA checklist. This is to be 
used when a more custom made contract is needed and provides guidelines 
for any negotiations. It divides the possible use of biological material into 
three different categories where the MTA content consequently will differ. 
The checklist is: 
 
• Basic terms 
- Description of MGRs (country of origin, place and date of 
isolation, strain reference number, identification data, name of the 
individual that has isolated the strain from in situ conditions or, if 
individual’s name is not available, the name of the institution (legal 
entity) that employed the individual at the time of the isolation of 
the strain); 
- Bona fide and sustainable use, following the CBD-principles; 
- Clause governing the payment of the costs of handling; 
- Type of transfer: transfer where distribution to 3rd parties is either 
excluded or possible (The choice between these two options is 
subordinate to the kind of recipients.). 
- Information about provider and recipient: names, addresses. 
• Use-specific terms 
Category 1: Use for test, reference, bioassay, control and training 
purposes. No commercial use. No IPRs on MGRs, derived 
technology and information. The recipient has to follow the 
protocols of standard test and reference procedures. 
Category 2: Use for research purposes. No commercial use. No 
IPRs on MGRs, derived technology and information. 
Category 3: Commercial use. Need for more precise MTA 
provisions on IPRs, information feedback, patent application and 
benefit-sharing (see additional terms). 
• Accompanying terms 
Mention of the country of origin, reference to the original PIC; 
previous MTA-terms if any. 
• Additional terms  
- IPR related to MGRs and derived technology, 
- Terms on training, technical and scientific co-operation, access to   
and transfer of technology, exchange of information and publication 
policy. Terms providing possibilities for capacity building in, among 
others, taxonomy and general microbiology for the provider of 
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microbial genetic resources should be emphasised and prioritised to 
compensations such as financial arrangements. 
- Conservation of MGRs. 
- Partnerships involving other stakeholders than provider and    
recipient of MGRs, including indigenous and local communities 
- Monetary terms: Initial, up-front payment; milestones payment and 
royalties payment. 
 
The Code of Conduct stresses the importance of non-ambiguous definitions 
and clear descriptions of use, as the term commercial use necessitates a 
more precise agreement beforehand. 
   Section I.6 deals with ABS, technology transfer and joint research. It reads 
that terms with regards to benefit sharing can be chosen to be negotiated on 
at the time of any commercial utilization of the biological material, but that 
preliminary benefit-sharing terms can be included when concluding the 
MTA. This is also the recommended cause of action. Likewise, it is 
recommended that the issue on IPRs to the MGR or associated technology is 
agreed upon before investments are made into research and development 
that could result in commercial use of the MGR or related technology.154  
 
4.5.3 The ISE Code of Ethics 
The International Society of Ethnobiology’s Code of Ethics has its origins in 
the Declaration of Belém (Brazil) agreed upon in 1988 at the Founding of 
the International Society of Ethnobiology. At the First International 
Congress of Ethnobiology, indigenous peoples from various parts of the 
world met with scientists and environmentalists to discuss a common 
strategy to stop the rapid decrease in the planet's biological and cultural 
diversity. The result was the Declaration of Belém, explicitly outlining the 
responsibilities of scientists and environmentalists in addressing the needs 
of local communities and acknowledging the central role of indigenous 
peoples in all aspects of utilization of biological resources. In 1998 the Code 
of Ethics was adopted. The ISE wishes to work in a genuine partnership and 
collaboration with indigenous/local communities in order to avoid past 
injustices. The objective is to build towards developing positive, mutually 
beneficial, and harmonious relationships in the field of ethnobiology.155
   The ISE recognizes the fundamental need for collaboration in order to 
optimize the outcome and to reduce adverse effects of R&D. It also 
acknowledges and supports the rights of indigenous peoples to the 
preservation, control and continued development of their heritage 
knowledge. For this purpose the Code consists of a set of principles, 
including the recognizing of indigenous peoples’ rights to self-
determination, to confidentiality, to give or veto PIC and to equitable 
compensation and sharing.156  
                                                 
154 MOSAICC, section I.6, p. 12. 
155 See http://ise.arts.ubc.ca/ethics.html, 05/04/06. 
156 See http://ise.arts.ubc.ca/ethics.html, 05/04/06.  
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   The Code of Ethics is further elaborated on in the complementing ISE 
Guidelines for Research, Collection, Databases and Publications.157 They 
define the concept of full disclosure and emphasizes that PIC and 
agreements for ABS are to be granted before undertaking any research, 
collection or publication. All activities are to be carried out with respect, 
understanding and good faith. Noteworthy is the commitment not to 
undertake any research, collection et cetera deriving or obtained from 
information/biological resources from any community that has requested a 
moratorium on research, collection or publication. This means that the 
information/biological resource accessed continues to be in the sphere of 
control of the communities, even after such information has left their de 
facto control.  
 
 
 
                                                 
157 See http://ise.arts.ubc.ca/research.html, 06/04/06. 
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5 National and Regional ABS 
legislation 
There are a number of countries that have adopted ABS rules concerning 
access to biological material. They are still on different stages of 
implementation. For example, the Philippines and India have implemented 
national legislation while a number of South American countries (the 
Andean Community) and African countries have adopted model legislation 
that have yet to be implemented on a national level. 
   The approach towards issues such as access to biological material, PIC, 
technology transfer, IPR in general and TK in particular, varies somewhat. 
However, where legislation has been implemented nationally, the practical 
examples seem to be scarce. This could be due to an extensively 
bureaucratic procedure. 
 
5.1 Philippines Executive Order 247 and 
its Implementing Rules and 
Regulations 
The Philippines pioneered the enactment of legislation in order to 
incorporate the objectives of the CBD into national legislation. Any 
reference to intellectual property was consciously avoided.158
   The Executive Order No. 247 entered into force in 1995 and was the result 
of a consultative process involving a wide range of different stakeholders.159 
The initiative and the first draft came from a network of natural product 
chemists. 160Consultations were subsequently held with academics and 
university scientists, government officials and at a later stage, with different 
government departments, NGOs, organizations representing indigenous 
communities and the (mainly Philippine) private sector.161
   After the Executive Order was signed by President Ramos in May 1995, 
work began on the Implementing Rules and Regulations. This was a process 
where drafts were circulated for comments to the different participants 
mentioned above. The final version was signed in June 1995.162  
   Although the legislation has been in force roughly for a decade, only two 
research permits have been issued, which could indicate that the procedure 
has taken a form too complex.163   
    
                                                 
158 Dutfield, 2004, p. 138. 
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160 Medaglia, supra f.n. 31, p. 186. 
161 Dutfield, 2004, pp. 138-139. 
162 Ibid. 
163 Ibid, p. 142. 
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5.1.1 Mutually agreed terms 
All bioprospecting depend on permission in the form of a research 
agreement between the bioprospector and the government. A research 
proposal must first be submitted to the government and a copy to any 
community affected. The EO distinguishes between an Academic Research 
Agreement (ARA) and a Commercial Research Agreement (CRA). There 
are minimum terms that apply to all agreements and a number that apply 
specifically to each agreement. 
The terms include, for the interest of this thesis; 
 
• Periodic reports on the collections made; 
• Availability of commercial products derived from Philippine resources 
to the national government and local communities concerned; 
• Equitable sharing of immediate, medium- and long-term benefits 
resulting from the bioprospecting among the stakeholders concerned; 
• The requirement that all the bioprospecting research, including 
subsequent technological development of a product be conducted in 
cooperation or collaboration with Philippine scientists from domestic 
institutions; 
• That any technologies developed be made available royalty-free for 
commercial and local use to the national government; 
• In case of a commercial product or technology is developed, an equity 
or remittance, the amount to be mutually agreed upon, shall be 
equitably shared between the Philippine government, protected areas 
fund (if the material or resources came from such an area) or the 
concerned indigenous/local community who gave the PIC, and with the 
individual who modified such material or resource that came from 
private property. 
• The requirement that a separate agreement be made for the transfer of 
royalties, benefits and technologies. 164 
  
5.1.2 Prior informed consent 
Under the Philippine legislation, prior informed consent must be obtained 
by the applicant from the concerned: local community; indigenous people; 
protected area management board or the private land owner. PIC 
presupposes full disclosure of the intent and the scope of the bioprospecting 
activity in a language and process understandable to the community. This 
must take place before any bioprospecting activity is undertaken.165 There is 
also a mandatory public notification requirement166 and followed by a two-
week waiting period, a detailed description of the activities proposed is to be 
presented by a legitimately convened assembly of the local communities 
                                                 
164 Columbia University, 1999, supra f.n. 84. 
165 Section 2 of the Implementing Rules and Regulations. 
166 Section 7.1.1, Implementing Rules and Regulations. 
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involved.167 Further a “categorical statement” that “such activity to be 
conducted will not in any way affect their traditional use of their resources 
is stipulated in Section 7.1.2.  
   PIC is not formally required from the state itself; rather a PIC certificate 
issued by the different stakeholders mentioned above must follow any 
application. However, considering the detailed terms necessary for any 
research agreements to be granted a de facto PIC requirement can be said to 
exist.168
 
5.1.3 Benefit sharing, technology transfer, joint 
R&D 
The Implementing Rules and Regulations refer to benefit sharing as the 
sharing of the results of bioprospecting activity and the benefits arising from 
the commercialization and/or use of the biological/genetic resources, fairly 
and equitably with the stakeholders concerned (e.g. indigenous community 
or private land owner) by the Principal or Collector. Result and Benefits can 
be e.g. royalties, technology, training and joint research or capacity 
building.169
 
5.1.4 Protection of TK 
The legislation refers to the CBD which recognizes the close relationship 
between indigenous communities’ lifestyles and TK and the conservation of 
biological diversity. This ties the interests of the indigenous and local 
communities in the existing resources in their domain, to benefit sharing and 
the PIC procedure. Explicit rules however, only stipulate that ownership to 
resources accessed remains with the Republic of Philippines. Another 
stipulation can be found in ARAs where IP rights cannot be sought without 
prior consultation with the designated national agency.170 It does not, 
strengthen indigenous rights over their TK or solve the question on how to 
handle the transfer of TK to bioprospectors (other than through the PIC 
procedure) and the issues of intellectual property rights of commercial 
products deriving from TK.  
 
                                                 
167 Section 7.1.2, Implementing Rules and Regulations. 
168 Ibid. 
169 Ibid, p. 141. 
170 Medaglia, supra f.n. 31. 
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5.2 The Andean Community Decision 391  
The Decision 391, establishing a common system on access to genetic 
resources, was adopted by the Andean Community171 member states in 
1996. It was the result of a two-year process where the participation of 
indigenous communities and NGOs was intended to be a vital part through 
workshops and comments. Unfortunately in 1994 at a workshop, attended 
by NGOs and a large number of indigenous peoples’ organizations, the 
second draft report was misinterpreted by some groups as being draft law 
and they sought to have it rescinded. The result of the misunderstanding was 
that civil society involvement in the process became more limited.172   
   The scope of the decision is set out in Article 3. It applies to: 
 
• Genetic resources for which the member countries are countries of 
origin; 
• Their derivatives and intangible components; and 
• The genetic resources of migratory species found for natural reasons in 
the territory of the member countries. 
 
Article 2 establishes the objectives of the Decision which generally are to 
regulate access to genetic resources and their derivatives in order to: 
 
• Establish the conditions for fair and equitable sharing of the benefits 
arising from such access; 
• Establish a basis for the recognition and appreciation of genetic 
resources, their derivatives and related intangible components, 
especially when involving indigenous, Afro-American and local 
communities; 
• Encourage the conservation of biodiversity and sustainable use of 
biological resources containing genetic resources; 
• Promote the consolidation and development of scientific, technological 
and technical capacities at local, national and subregional level; and 
• Strengthen the negotiating capacity of the member countries. 
 
The Decision echoes the CBD in affirming the countries’ sovereign rights 
over their biological resources; however, it has by establishing rights over 
the derivatives of such resources, gone further than the CBD. 
   Derivatives should be differentiated from a synthesized product which is a 
product obtained through an artificial process, using genetic information. An 
example of a derivative would be an herbal formulation while a synthesized 
product would be a pharmaceutical compound modelled on a natural 
compound.173
                                                 
171 Formally known as the Cartagena Accord and also previously commonly referred to as 
the Andean Pact. The Andean Community countries are: Bolivia, Colombia, Ecuador, Peru 
and Venezuela. 
172 Dutfield, 2004, p. 143. 
173 Ibid, p. 144. 
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Intangible component refers to any knowledge, innovation or practice of 
actual or potential value associated with the genetic resource or its 
derivative. It does not have to be protected by intellectual property 
systems.174  
   The Andean Pact has been criticized for assigning tenure of biological 
resources to communities but reserving exclusive property rights for the 
state, thus limiting the distribution of benefits through a state-owned 
property regime while obligating communities to preserve the resources.175
 
5.2.1 Mutually agreed terms 
Access is conditioned by an application (including a project proposal) and a 
contract. The party other than the applicant is the State concerned, 
represented by the competent national authority. The contract will stipulate 
a variety of conditions including; 
 
• Strengthening of mechanisms for technology and knowledge transfer 
(including biotechnologies), which are culturally, socially and 
environmentally safe and healthy; 
• Development and strengthening of the capacities of indigenous, Afro-
American and local communities relating to the intangible components 
associated with genetic resources and their derivatives; 
• An obligation to inform the competent national authority of the results 
of the research carried out. 
• Terms of transfer of accessed materials to any third party.176 
 
If access is sought to a genetic resource with an intangible component, an 
annex must be included in the contract with a scheme on fair and equitable 
sharing of any possible benefits arising from that component. The annex 
must be signed by the supplier of the intangible component however, there 
is no clear stipulation that the signer has to be a representative of the 
indigenous, Afro-American or local community.177  
 
5.2.2 Prior informed consent  
There is no explicit reference to PIC in the decision although applicants are 
required to provide all available information of the genetic resource 
including the actual and potential use of the resource, its derivatives and 
associated intangible components. It is not necessary to provide this 
information to any other stakeholder group.178
                                                 
174 Dutfield, 2004, p. 144.  
175 Environmental Policy Studies Workshop, School of International and Public Affairs, 
Columbia University, 1999, Access to Genetic Resources: An Evaluation of the 
Development and Implementation of Recent Regulation and Access Agreements, p. 11. 
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 5.2.3 Benefit sharing, technology transfer, joint 
R&D 
The Decision incorporates technology transfer into the access contracts. 
Joint research is referred to in Article 10 but only in the context of 
subregional cooperation and is not specifically a requirement linked to 
access procedure. 
 
5.2.4 Protection of TK 
Traditional communities are not directly referred to as potential parties to 
ABS contracts. They are recognized only as suppliers of TK, or as potential 
landowners. Thus they become dependent on prior recognition of their land 
rights or intellectual right to their TK, something which is not necessarily 
always the case. 
   Another issue is the Decision affirmation of sovereign rights over 
derivatives of genetic resources and the potential conflict with Article 8 (j) 
CBD. This could include plant extracts which traditional remedies often 
consist of. The Decision further excludes from its jurisdiction the exchange 
of genetic resources, and its derivatives and related intangible components 
among traditional communities for their own use, thereby complicating the 
issue.179  
   IPRs obtained from genetic resources, derivatives, synthesized products or 
intangible components through violating the terms of access will not be 
recognized in any of the Andean Community member states. If national IPR 
offices encounter an application for protection of a product or technology 
where there is evidence that the genetic resource180 originates from a 
member state, they must require the applicant to submit a copy of their 
access contract as a precondition of the concession of any IPR.181
 
5.3 The Costa Rica Biodiversity law 
In April 1998 the Ley de Biodiversidad was passed. Although Costa Rica is 
a small country it is estimated to hold nearly 4 percent of the world’s 
biodiversity.182 At that time six individual contracts with transnational 
companies had been signed.183  
The Costa Rica Biodiversity Law was as well created through an extensive 
consultation process involving indigenous people, small farmer groups, 
                                                 
179 Dutfield, 2004, pp. 146-147. 
180 and/or its derivatives and intangible components.  
181 Decision 391, Complementary Provisions, Second and Third.  
182 http://www.inbio.ac.cr/en/biod/bio_biodiver.htm, 14/03/2006. 
183 One of these is the now famous contract between INBio and Merck, a pharmaceutical 
company. 
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legal experts, scientists, civil servants and representatives of the private 
sector. The first draft was published in 1996 and became the subject of a 
wide and conflicting range of views which delayed the process.184  
   Coming into force as Law No. 7788 in May 1998 it is an elaborate 
national law implementing the CBD and it covers all issues contained in the 
CBD, including, for the interest of this thesis, PIC, scientific and traditional 
biodiversity-related knowledge protected through IPRs and/or sui generis 
systems, and technology transfer. The Biodiversity Law has 10 chapters 
where two deal with ABS. Chapter V deals with access to genetic 
components, biochemicals and protection of associated knowledge. The 
chapter includes section III which contains protection of intellectual and 
industrial property rights. Article 83-85 set out a framework for developing 
a sui generis system for intellectual community rights which are recognized 
in the law. Chapter VI deals with education and public awareness, research 
and technology transfer, where Article 88 specifically deals with research 
and technology transfer (including biotechnology) related to biodiversity.  
 
5.3.1 Mutually agreed terms 
The definition of PIC states that it is the 
 
“Procedure through which the State, private owners or the 
local or indigenous communities, as the case may be, properly 
supplied with all the required information, allow access to 
their biological resources or to intangible components 
associated to them, under mutually agreed conditions.”185
 
Article 63 links mutually agreed terms to terms of benefit sharing such as 
technology transfer and the equitable sharing of any potential benefit 
stemming from the resource. Additionally, it preconditions that the type of 
protection demanded from suppliers of TK is identified and complied with. 
Another condition is domestic legal representation for natural or legal 
persons not residing in Costa Rica. 
 
5.3.2 Prior informed consent   
The procedure to obtain PIC is not elaborated upon in the Biodiversity Law. 
However, the application for access to biogenetic resources is 
preconditioned by an attached PIC from the appropriate stakeholder 
group.186
 
   
  
                                                 
184 Dutfield, 2004, pp. 148-149. 
185 Article 7.9. 
186 Article 63.1. 
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5.3.3 Benefit sharing, technology transfer, joint 
R&D 
An immediate remuneration is required in Article 76, which states that 10 % 
of the research budget is to be deposited in favour of the party that provides 
access to the resource. The party could be e.g. an indigenous community 
providing TK or access to their land, or a private land owner. Other forms of 
technology transfer can also form part of the access procedure but they are 
not explicitly mentioned in the Biodiversity Law. Long-term benefit sharing 
such as payment or potential IPRs obtained from the commercialization of a 
product or technology, stemming from accessed resources is further not 
mentioned in the Biodiversity Law. 
   
5.3.4 Protection of TK 
Article 77 of the Law acknowledges the need for protection of innovation 
and knowledge through intellectual property rights. The State goes on to 
specify what kind of protection it offers, such as patents, copyrights, 
farmers’ rights, trade secrets etc. Further, the sui generis right of community 
intellectual rights is recognized. Article 82 states: 
 
The State expressly recognises and protects, under the common 
denomination of sui generis community intellectual rights, the knowledge, 
practices and innovations of indigenous peoples and local communities 
related to the use of components of biodiversity and associated knowledge. 
This right exists and is legally recognised by the mere existence of the 
cultural practice or knowledge related to genetic resources and 
biochemicals; it does not require prior declaration, explicit recognition nor 
official registration; therefore it can include practices which in the future 
acquire such status. 
This recognition implies that no form of intellectual or industrial property 
rights protection regulated in this chapter, in special laws and in 
international law shall affect such historic practices. 
 
The community intellectual right is somewhat similar to copyrights in the 
sense that it does not require any formal registration in order to be 
recognized. Perhaps one could also compare it further to the length of the 
copyright, life of the creator plus seventy years.187 As the community right 
is not held by an individual or group of individuals as such but to a 
community whose lifespan is longer than any of the individuals forming that 
community, the intellectual property right is protected for as long as the 
community exists. However, copyright protection is not available as it is as 
part of the intellectual property system an individual right by nature. 
 
                                                 
187 According to the Berne Convention for the Protection of Literary and Artistic Works, of 
September 9, 1886. 
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5.4 The African Model Legislation for the 
Protection of the Rights of Local 
Communities, Farmers and Breeders, 
and for the Regulation of Access to 
Biological Resources 
The African Model Legislation seeks to cover both ABS issues and provide 
an IPR instrument adjusted to the African continent context. It was adopted 
in 2000 and is, as the title suggests, model legislation, not intended for 
immediate national implementation. Instead it provides a framework, in 
compliance with both the CBD and TRIPs for the member states of the 
OAU188 to craft specific national legislation adjusted to their own needs.189 
There are several underlying core elements of the Model Law all reflecting 
the particular African context, such as food sovereignty and security, 
community rights and responsibilities, and fair and equitable benefit 
sharing. The position of the OAU member states in negotiating in the WTO 
and with the industrialized world is also a matter of focus.190 The need for 
capacity building in the form of participation in research and development 
rather than financial benefits is emphasized as well as the current trend 
towards Africa’s biological resources becoming another trade commodity 
between North and South.191    
    
5.4.1 Mutually agreed terms 
Biological resources can be accessed under varying contracts. The access 
permits can be academic research permits, commercial research permits and 
commercial exploitation permits.192 Different permits may not be used at 
the same time on the same resource unless granted so in written form.193 
The material accessed cannot be transferred from the country in question 
without a Material Transfer Agreement. Regular status reports must be 
submitted to the National Competent Authority on the progress of the 
research and development on the resource and if large quantities are 
collected, on the ecological state of the area.  
 
                                                 
188 The Organization for African Unity, now the AU, African Union with 53 member states. 
189 Ekpere, J. A, 2000, The OAU’s Model Law, The Protection of the Rights of Local 
Communities, Farmers and Breeders, and for the Regulation of Access to Biological 
Resources, An Explanatory Booklet, p. 3. 
190 Ibid, pp. 10-15. 
191 Ibid, p. 28. 
192 OAU Model Law, Article 13. 
193 Article 13 (2). 
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5.4.2 Prior informed consent 
To obtain an access permit it is necessary to first get PIC from both the State 
and the local/indigenous community concerned. The PIC must be 
enlightened, meaning that the information provided by the applicant must be 
fully understandable to the ones giving the PIC.194 It must be ensured that 
women also are involved in the decision making.195 PIC is a precondition 
for the granting of any access and if the requirement is not met the permit 
can be unilaterally withdrawn by the National Competent Authority. The 
Model Law further recognizes the Community Intellectual Rights and other 
Community Rights and provides the right to refuse consent and access.196
 
5.4.3 Benefit sharing, technology transfer, joint 
R&D 
The definition of benefit sharing in the OAU Model Law is: 
 
“The sharing of whatever accrues from the utilization of 
biological resources, community knowledge, technologies, 
innovation and practices.”197
 
The practical mechanisms are however not further elaborated on. The 
possible forms of benefit sharing are not very detailed; Article 12 speaks of 
the monetary share of the earnings arising from the biological resource 
and/or TK. The earnings can be directly or indirectly stemming from the 
access. At least fifty per cent of those benefits are to be channelled back to 
the concerned community. The explanatory booklet to the Model Law 
emphasizes the need for non-financial benefit sharing in terms of enabling 
the development of the OAU countries. 
 
5.4.4 Protection of TK 
The OAU provides an ambitious framework for protecting TK. Two terms 
are adopted, community rights (including community intellectual rights) and 
farmers’ rights. The rights are recognized by the State as enshrined under 
the norms, practices and customary law of the concerned local/indigenous 
community.198
   Patent protection for life-forms and biological processes are banned in 
Article 9 and consequently a collector cannot apply for such a patent in 
connection with accessed biological resources. IPR protection on product or 
                                                 
194 Ekpere, The OAU’s Model Law, p 27.  
195 OAU Model Law, Article 5 (1)(ii). 
196 Articles 16, 19 and 23. 
197 OAU Model Law Article 1. 
198 Part IV and V of the Model Law, Articles 16-27. 
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technology associated with the biological resource will not be granted 
without the PIC of the original providers.199
   
5.5 Comparing the different ABS 
legislations 
A relevant question is whether it is suitable to combine IPR rules with ABS 
legislation. There is no doubt that the issues are closely related, however, to 
introduce provisions such as the ban on the patenting on life-forms as in the 
OAU Model Legislation into ABS legal instruments can give the 
appearance that the problem with IPR protection of rights that do not fall 
under the conventional IPR system is solved. 
   With the exception of the Philippine and the Costa Rican law the rest have 
yet to be implemented. This presents a problem in that it is difficult to 
evaluate the advantages and disadvantages of the different solutions. The 
Philippine law does not mention IPRs while the Andean Community and the 
OAU have created sui generis terms for TK. The Costa Rican Biodiversity 
Law expressly recognizes in Article 82 what is called the sui generis 
community intellectual rights. However, although the existence and the 
obligation to protect such rights are acknowledged, the nature and scope of 
the rights remain to be identified.   
 
Mutually agreed terms: 
All national ABS regimes are more or less implementing the CBD 
convention which created the states’ sovereign rights to their resources.200 
Access must thus be granted by the state through the designated National 
Competent Authority. This takes place through a contract which character 
varies depending on whether it is a research or commercial contract, 
provided for in the Philippine EO and OAU Model Law. It seems 
reasonable to be less demanding of academic research than of commercial 
research but, as Dutfield points out; it can be difficult to distinguish between 
such researches.201 However, as not all of the legislations are constructed as 
the Costa Rican Law which applies different fees for domestic and foreign 
applicants, too onerous terms can be detrimental to the national interest.202
   The terms includes terms of benefit sharing, obligation to inform of 
research results and, in the case of the Philippine legislation, obligation to 
include Philippine scientists from domestic institutions in the bioprospecting 
research or development of the biological resource.  
 
Prior informed consent: 
As to who is to give PIC different options have been chosen. The Philippine 
and Costa Rican laws require PIC to be obtained from the concerned 
local/indigenous community, protected area management or the private land 
                                                 
199 Dutfield, 2004, p. 159. 
200 Article 3, CBD. 
201 Dutfield, 2004, p. 160. 
202 Ibid. 
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owner, not from the State itself. The Andean Community Decision 391 only 
requires PIC from the State. The OAU Model Law has opted to require PIC 
from both the indigenous/local community concerned and from the State. 
   The definition of what is required for a PIC to be properly informed is 
most elaborated upon in the African Model Law Article 4 (1). The Costa 
Rican legislation mentions PIC as the approval after being properly supplied 
with information and the Philippine EO states that the consent is to be 
obtained in accordance with the customary law of the concerned 
community.203 The implementing Rules and Regulations of the EO 247 
require the full disclosure of the intent and scope of the bioprospecting 
activity in a language and process comprehensible to the community before 
any bioprospecting activity is initiated.204
   Equally important as the requirement to obtain PIC is the right for 
indigenous/local communities to refuse or to withdraw PIC. The Philippine 
EO only provides for the rescission of an agreement in cases where the PIC 
has been obtained through fraud, stealth, false promises and/or 
intimidation.205 The Costa Rican Law 7788 on the other hand recognizes the 
right to “cultural objection”, be it for cultural, spiritual, social, economic or 
other motives.206 The African Model Law provides for the withdrawal or 
restriction of PIC when the access activities are likely to be detrimental to 
the concerned community’s socio-economic life, or its natural or cultural 
heritage.207 However, the Model Law accepts those grounds of objection 
regardless of whether they are prior to or after the access has been granted. 
   Regarding the PIC’s status in applications for IP protection again, 
different solutions are devised. The Costa Rican Biodiversity law 
preconditions the granting of IP protection to consultations between the 
Patent Office and the Technical Office for the confirmation that the 
applicant obtained PIC. Justified opposition from the Technical Office will 
result in the refusal of the IP application.208 The Decision 391 also provides 
a copy of the access contract, when there is certainty or reasonable 
indication that the product or process emanates from biological resources 
originating from any of the member states. If the product/process has been 
obtained through non-compliance with the decision, protection shall be 
refused.209 The OAU Model Law prohibits in Article 8 (v) the collector to 
apply for IP protection but it does not provide for a procedure in case of 
such an application. The Philippine legislation has, as mentioned above, not 
provided for any IPR rules. 
 
Benefit sharing, technology transfer, joint R&D:  
The different ABS legal instruments are strategically important for the 
countries capacity building. One example is India which has built a 
                                                 
203 Executive Order 247, section 2. 
204 DENR, Administrative Order, No 96-20, June 21 1996, Implementing Rules and 
Regulations on the Prospecting of Biological and Genetic Resources, section 2. Available 
at: http://www.psdn.org.ph/chmbio/dao20-96.html, 15/03/06. 
205 Section 9, Article 9.1.  
206 Costa Rica Biodiversity Law, Article 66. 
207 OAU Model Law, Article 20. 
208 Costa Rica Biodiversity Law, Article 80. 
209 Andean Community Decision 391, Complementary Provisions, second and third. 
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biotechnology industry which is competitive on the international arena.210 
The long-term benefits should not only be directed towards technologies 
appropriate for conservation purposes but also contribute to the 
advancement of the country as such, to increase wealth, education and to 
improve the health of the population.  
   Decision 391 is quite detailed in this respect. Article 35 states that an 
annex stipulating fair and equitable distribution of the profits arising from 
the access to genetic resources with associated “intangible components”, 
and the use thereof. Other typical access conditions are the participation of 
regional nationals in the research (also stipulated in the EO 247), 
strengthening of the transfer of technology (including biotechnology) and 
know-how, supply of information regarding science related to the genetic 
resource, all with the explicit aim to promote the consolidation and 
development of scientific and technological capacities at local, national and 
regional level.211 The African Model Legislation only briefly mentions 
monetary remuneration.212 The Costa Rican Law stipulates both a deposit of 
up to 10 percent of the research budget and the transfer of technologies 
relevant for the sustainable maintenance of biodiversity.213 The 
Implementing Rules and Regulations of the EO stipulate as a minimum term 
for access to be granted that all discoveries of commercial products should 
be made available both to the State and the concerned local community, that 
all bioprospecting research should be made in cooperation/collaboration 
with Philippine scientists and that if any technology is developed it should 
be made available to the Philippine government royalty-free.214 However, 
the legislation provides for the possibility of negotiating agreements with 
other terms, if appropriate. 
 
Protection of TK: 
Although all of the different legal instruments acknowledge the fundamental 
importance of preserving and maintaining TK, a developed system for this 
is lacking. The different legislations require benefits to be shared with the 
holders of the TK215 provided. Sui generis systems of community 
intellectual rights are created but not very elaborated on in two of the 
instruments, the OAU Model Law and the Costa Rican Biodiversity Law. It 
is however clearly stated in Article 79 of the Costa Rican Biodiversity Law 
that any decisions made within separate conventional intellectual property 
system related to biodiversity must be in congruence with the Biodiversity 
Law’s objectives, thus putting the objectives of the CBD and its Article 8 (j) 
first. 
   The Philippines, the first country to enact ABS legislation has chosen to 
separate IPR legislation from the rules of access to biological resources. 
Draft legislation concerning the protection of community intellectual rights 
protection (CIRPA) has been developed and presented by Philippine Senator 
                                                 
210 Dutfield, 2004, p. 174 and forward. 
211 Articles 2 (d) and 17. 
212 OAU Model Law, Article 13. 
213 Costa Rican Biodiversity Law, Articles 76 and 88. 
214 DAO Implementing Rules and Regulations, Articles 8.1 (9), 8.1 (12) and (13). 
215 Such as the EO 247. 
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Flavier in 2001 but has yet to be adopted.216 However, the draft law 
establishes community rights ownership through registration, while still 
being distinct and separate from patent law.217 In the case of inventions, 
industrial designs and utility models the register would be managed by the 
Bureau of Patents, Trademarks and Technology Transfer (BPTTT), thus 
enabling for easy access when any application is to be appraised.218 With 
the registries, the Philippines can award community claims over TK and 
establish a working sui generis system without involving the conventional, 
cumbersome patent system.219
   The Andean Community Decision takes on a different approach. State 
sovereignty is emphasized while indigenous people’s right and authority 
over their TK is recognized and valued.220 The Decision also stipulates that 
access contracts shall bear in mind the rights and interests of the suppliers of 
genetic resources and their by-products with associated intangible 
components and it goes on to require equitable and fair sharing of the 
benefits.221 The Complementary Provisions of the Decision requires 
national offices of intellectual property to request the serial number of the 
access contract when there are indications that the genetic resource for 
which IP protection is sought originates in one of the member states of the 
Andean Community. A system for exchanging information about access 
contracts and IP protection awarded is also to be set up.  
   So how is the TK protected in the Decision? The different ABS 
instruments have in common that indigenous/local community knowledge 
enjoys protection; the question is only of what kind. National sovereignty is 
emphasized over the absolute right of indigenous people to their knowledge, 
innovations and practices. There seems to be other factors at play. 
   There is no doubt that the States’ need to conform to TRIPs has an impact 
on the different solutions chosen. It is reflected in the OAU Model Law’s 
ban on patents on life and in the Philippines EO 247 concentration on access 
and benefit sharing, excluding all IPR. Costa Rica has taken the most 
pragmatic stand and is in the process of developing sui generic protection 
for TK in a consultative process, something that undoubtedly take time.  
   The Andean Community is politically marked by marginalization and 
oppression of indigenous communities, a legacy of colonialism. Many 
communities are in active opposition with their States in issues regarding 
land rights and more generally their position as citizens of their country.      
  
  
    
 
 
                                                 
216 Community Intellectual Rights Protection Act, 2001, S. No. 101. 
217 Ibid, Section 2 (b). 
218 Ibid, Section 6 (c). 
219 Blanco, J.L.B, 2000, Harnessing Traditional Knowledge for Development and Trade: 
the Bicol (Phils.) Experience, report prepared for UNCTAD Expert Meeting on Systems 
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Geneva 30 Oct–1 Nov 2000. 
220 Andean Community Decision 391, Article 7. 
221 Andean Community Decision 391, articles 34 and 35. 
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5.6 EC View on TK and Access and 
Benefit Sharing 
Dealing with biogenetic resources and TK does not wholly come under EC 
competence. EC measures concerning ABS, such as aspects of IPRs, relate 
to the internal market while other aspects, such as bi/multilateral 
negotiations, trade, international development co-operation et cetera, lies 
within the sovereign control of the Member States.222
   Nevertheless, access and benefit sharing and related questions of TK are a 
source of discussion within the EC. The European Parliament has, in 
preparation for the COP meeting in Brazil, March 2006, called for the 
establishment of a legally binding ABS instrument and for the EC 
Commission and Member States to ensure that the CBD work programme is 
implemented with the full participation of indigenous/local communities.223   
   In a Communication from the European Commission to the European 
Parliament the EC policy is further explored.224  
   Europe is historically an important user of biogenetic resources in both 
research and product development. Europe is further a provider of such 
resources home to a rich biodiversity, including the Mediterranean 
“hotspot” (biodiversity rich areas), as well as harbouring a large number of 
ex situ collections such as botanic gardens and microbial culture collections. 
Some of these institutions have developed policies to facilitate the access 
and exchange of material in line with CBD and applicable national laws, on 
an individual basis and as members of broader networks.225  
   The level of demand for biogenetic resources within the EU and across 
different industrial sectors is difficult to estimate and shifts with time, e.g. in 
line with technological innovations. Nevertheless, the EU possesses 
substantial commercial R&D capacity and European life sciences industry 
constitutes an important sector of the European economy. 
   The Commission and the Member States were active participants in the 
negotiations leading to the adoption of the Bonn Guidelines and it is stated 
that implementation of the voluntary document is an issue of equity and 
fairness. It is also seen as an enhancement of the credibility of the EC.226
The EC has yet to introduce comprehensive legislation governing ABS or to 
facilitate the protection of TK. Although the recital (55) in the EC 
Biotechnology Directive227 contains an obligation for Member States to 
fully take into account Article 8(j) CBD, and related provisions in the 
                                                 
222 Second Report of the European Community to the Convention on Biological Diversity: 
Thematic Report on Access and Benefit-Sharing, October 2002, p.1. 
223 European Parliament resolution on preparations for the COP-MOP meetings on 
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225 Supra f.n. 223, p. 4. 
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227 Directive 98/44/EC (6 July 1998) on the legal protection of biotechnological 
innovations. 
 59
adoption of national laws, regulations and administrative provisions, the EC 
position on, for example, a disclosure of origin requirement in patent law is 
ambivalent (see above chapter 5.1). The encouragement in recital (27)228 of 
the same Directive cannot be said to constitute any pressing legal obligation 
for the patent applicant. The matter is further complicated by Article 1.2 of 
the Directive which states:  
 
This Directive shall be without prejudice to the obligations of 
the Member States pursuant to international agreements, and in particular 
the TRIPs Agreement and the Convention on Biological Diversity. 
 
This does not mean that there has not been any further activity in this area of 
law. Various institutions, networks and companies within the EC have been 
involved in the development of voluntary codes of conduct in order to 
provide a framework for ABS arrangements. These efforts have been 
supported by the EC, e.g. the Micro-organisms Sustainable Use and Access 
Regulation International Code of Conduct (MOSAICC) between 1997-
1999.229
   The EC recognizes in the Commission Communication the fact that the 
intellectual property system “plays a practical role in promoting the sharing 
of the benefits from access to genetic resources and associated TK”.230
It is argued that requirements that can entail the disclosure of origin of 
genetic resources and TK already exist under EC law and European 
intellectual property law. In line with established patent principles, three 
cases are provided for: the so-called enabling disclosure; the relevant prior 
art; and the identification of the true inventor(s). 
   Traditional knowledge, innovations and practices (TK) should be 
protected, both as an indispensable tool in the conservation and sustainable 
use of biodiversity, and to ensure the fair and equitable sharing of the 
benefits arising from the use of such knowledge, with the involvement and 
approval of its holders. The full involvement of indigenous and local 
communities in the negotiations of an international regime on ABS is 
encouraged. The continued cooperation between the CBD and WIPO is 
desirable.231                                                                                        
   The EC has actively put forward its opinion on the issue of TK and a 
proposed disclosure requirement in the TRIPs Council. As mentioned above 
(chapter 5.1) the EC is positive towards examining ad discussing the 
                                                 
228 It states: Whereas if an invention is based on biological material of plant or animal 
origin or if it uses such material, the patent application should, where appropriate, include 
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possible introduction of a TK tracking system. This would enable Members 
and their authorities to monitor all patent applications relating to biogenetic 
resources at a global level. It is seen as a good solution that would ensure 
transparency and be helpful towards checking whether contractual 
arrangements are being respected. Nevertheless, the EC is of the firm 
opinion that such disclosure requirement should in no way affect the balance 
of rights and obligations laid down in the TRIPs Agreement. It should not 
disturb the rights of WTO Members to create a favourable environment for 
R&D activities in the field of biotechnology. The patent system should 
continue to be a highly effective tool for stimulating innovation, 
technological progress and economic development.232
   The EC has further proposed ‘an indispensable measure that could make 
the disclosure requirement an effective incentive to comply with access and 
benefit-sharing rules’. This is to introduce a simple notification procedure to 
be followed by patent offices. The patent office, which received a 
declaration of the country of origin or source of the genetic resources and/or 
associated TK, should notify this information to a centralized body. The 
Clearing House Mechanism233 of the CBD would be an adequate central 
body to which the patent office should send the information.234  
 
 
 
                                                 
232 Council for Trade-Related Aspects of Intellectual Property Rights, Minutes of Meeting, 
on 25-26 and 28 October, 29 November and 6 December 2005, 31 January 2006, 
IP/C/M/49, para. 122.  
233 Body within the CBD, coordinated by the Executive Secretary. The meaning of the term 
clearing-house is today extended to include any agency that brings together seekers and 
providers of goods, services or information, matching demand with supply. 
234 Supra f.n. 233, para. 126. 
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6 Analysis 
This thesis has aspired to give an overview of the issues surrounding 
bioprospecting. As the reader has acquainted itself with the material it 
should have become apparent that the relationship between IPRs, TK and 
ABS is complex, although intrinsically linked.   
   The link between conservation of biodiversity and TK is normally taken 
for granted as a “common knowledge” basis when discussing IPRs, 
biological resources and TK. The correlation deserves nevertheless to be 
explicitly discussed. TK has normally developed over an extended period of 
time, within a defined group of people, and adapted to a distinct sphere of 
biodiversity in which that group of people has lived. Biodiversity 
conservation is dependent of sustainable use of the open-access biological 
resources, more easily upheld when there is a defined community using 
them. The knowledge is not only comprised of medicinal properties of 
biological material but also relates to harvesting techniques. Sustainable use 
and biodiversity conservation may not be directly impacted by 
bioprospecting for pharmaceutical or biotechnological (especially third 
generation biotechnology). It becomes more of a pressing issue in natural 
remedy medicine or within the cosmetic industry where over-harvesting can 
pose an imminent threat to biodiversity. Regrettably this area has been 
outside the scope of the thesis.    
   Let us glance back to an initial question posed at the beginning of the 
thesis. Is the patent system applied correctly or can the problems envisaged 
by many developing countries and NGOs be remedied by a more narrow 
application of the patentability criteria, novelty, inventive step and industrial 
application? Generally, broad patents granted on information products in 
fundamental research will foster fundamental research. Likewise, narrow 
patents imply higher diffusion of research that has developed beyond 
fundamental research. It has been argued that it will be followed by 
relatively more applications and small improvements.235 The obvious 
answer would be an appropriate trade-off between stimulating third 
generation biotechnology, on the more advanced level of research, and to 
apply the patentability criteria in a stricter manner to patent applications 
relating to “raw” material such as biological resources and associated TK.      
Otherwise the tightened IPR regime that is imposed on developing countries 
through the implementation of the TRIPs Agreement will aggravate or 
strengthen biodiversity conservation.236   
 
                                                 
235 Janssen, J, Property rights on genetic resources: economic issues, Global Environmental 
Change, 1999, Vol. 9, iss.4, p.319. 
236 Ibid, pp. 313-321. 
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6.1 Protection of TK 
It cannot be emphasized enough that in order to make ABS instruments and 
protection of TK work, the industrialized countries need to take their 
responsibility. Although legal frameworks are developed by the countries 
rich in biodiversity and associated TK, they are limited in their scope and 
jurisdiction. The fact that IPR protection can be denied in the region where 
the biological resource was accessed is made redundant when the applicant 
can get patent protection in the EC or the US. In terms of capacity-building 
and development of a global market where local communities are to 
compete on strong markets such as the American one, the US patent 
awarded may prove to be detrimental. The free trade is, in this case, only 
flowing in one direction.  
   From the perspective of the legitimacy of the intellectual property system 
as such, the recognition and inclusion of PIC in the conventional IP system 
is essential. In intellectual property law, equitable principles require the 
refusal to grant or to enforce intellectual property rights when they would be 
or have been procured by fraud or deception.237 The contrary would allow 
the intellectual property system to assist and reward the conduct contrary to 
honest commercial practice. From this aspect, the requirement to disclose 
evidence of PIC in patent applications is critical to advancing a more 
equitable and balanced international intellectual property system.  
   The protection afforded to undisclosed information in TRIPs Article 39 is 
widely considered to be essential for encouraging technology transfer. It is 
however uncertain whether such protection would be suitable for TK.  
   In documents prepared by GRULAC238, for the WIPO Committee on the 
Relationship between Intellectual Property, Genetic Resources and 
Traditional Knowledge in 2000, it is stated that such protection would make 
it possible for monitoring access, exploitation and communication of TK to 
third parties. It is seen as an opportunity to control the means of 
dissemination of TK and to benefit from its exploitation.239  
   There have also been efforts made towards the forming of cartels. Such a 
project was carried out in Ecuador under the name of “The Transformation 
of Traditional Knowledge into Trade Secrets". The project attempts to 
achieve a cartelization of traditional knowledge within Ecuador and then 
expand the organizational structure to neighbouring countries. The 
knowledge from different ethnic groups wishing to participate in the project 
is being catalogued and deposited in a restricted access database, in which 
each community or group has its own file. Checks are made to verify 
whether different groups or communities have the same knowledge; if so, 
(future) benefits will be shared among all those groups sharing the same 
knowledge. Checks are also made to see whether each item of knowledge is 
                                                 
237 Perrault, and Oliva, ICTSD/CIEL/IDDRI/IUCN/QUNO ‘Dialogue on Disclosure 
Requirements: Incorporating the CBD Principles in the TRIPS Agreement On the Road to 
Hong Kong’ WTO Public Symposium, Geneva, April 21, 2005. 
238 the Group of Countries of the Latin America and the Caribbean. 
239 GRULAC Traditional knowledge and the need to give it adequate intellectual property 
protection, WO/GA/26/9, September 2000. 
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not already in the public domain. TK outside the public domain can be the 
subject of standardized MTAs. 
   A potential problem in this particular project is that the parties to the 
contract will be the interested company and the Government. The 
Government is required to share the benefits with the communities 
concerned, thus its willingness to actually do so will largely determine the 
success of the project.240
 Nevertheless, there are examples (e.g. India) where a long established 
history and documentation of TK, as well as a large number of practitioners 
and a supporting industrial sector, conventional IPRs serve as incentives for 
innovation based on the documentation. 
   As a final observation on the issue of TK protection, international 
legislation regulating the issue of ABS and TK does not seem to be suitable 
for preserving, protecting and promoting TK. When looking closer at 
regional and national regimes no one model emerges, rather there are 
considerable variations. Different cultural and legal systems require 
adaptation to local conditions.  
 
6.2 Stimulation of bioprospecting through 
ABS legislation 
Instead of providing a flexible legal framework for facilitated access to 
biological resources and adequate protection for TK, ABS legislation can be 
seen as rigorous, in fact deterring research and possible financial benefits. 
However, it is the view of the author that with the tide of a very intense 
biopiracy discussion, the biodiversity-rich countries (mainly the South) are 
trying to compensate for the non-stringency of the industrialized (North) 
countries’ IPR legislation, thereby implementing restrictive rules that 
unintentionally hinders scientific research, whether academic or 
commercial. One example is the Philippine EO247. Instead of facilitating 
access to genetic resources it appears to have hindered research. Since the 
enactment (1995), more than 30 applications have been made but several of 
those have been withdrawn. Only two ARAs had been approved by mid-
2002, one covering parts of the University of the Philippines and the other 
for the International Rice Research Institute (IRRI). The only CRA to be 
approved was a joint undertaking between the Philippine Department of 
Agriculture, the University of the Philippines and the University of Utah, 
funded by the US National Cancer Institute and US National Institutes of 
Health. The research objective is to collect marine organisms, to isolate 
active metabolites241 and to perform systematic inventories of the 
biodiversity of various habitats in the Philippine marine eco-system.242    
                                                 
240 TRIPs, CBD And Traditional Medicines: Concepts And Questions, Report of an ASEAN 
Workshop on the TRIPS Agreement and Traditional Medicine, Jakarta, 13-15 February 
2001. 
241 Metabolites are the intermediates and products of metabolism. The term metabolite is 
usually restricted to small molecules. A primary metabolite is directly involved in the 
normal growth, development, and reproduction. A secondary metabolite is not directly 
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It has been suggested that the major industrial nations have abdicated their 
responsibility to institute measures to ensure equitable access and benefit-
sharing arrangements. They have been slow to develop legal measures to 
ensure that the acquisition and use of biogenetic material and associated TK 
by persons, institutions and corporations in user countries are carried out in 
compliance with the laws in source countries and with the provisions of the 
CBD. For example, none of the IPR systems of the industrialized countries 
requires that patent applications for inventions based on genetic inventions 
or associated knowledge acquired in another country has to prove that the 
resources or knowledge were acquired in compliance with the CBD or 
national law in the source country.243  
   Of the different national and regional legislation surveyed here, only two 
are in force, the Philippine EO and the Costa Rican Biodiversity law. It 
would be particularly interesting to further study the implementation process 
of the OAU Model Law as it emphasizes the intellectual rights of 
communities. Opting for a sui generis protection system seems to be the 
general route of action for developing countries. Costa Rica who by many is 
put forward as a successful example has not yet enacted any such legislation 
although TK is acknowledged in the Biodiversity Law.  
   Notwithstanding the flaws of the current law, Costa Rica can be used as an 
example where bioprospecting has facilitated technology transfer and the 
development of domestic competence. In my opinion, this is the main 
advantage with national ABS legislation. It can provide, via explicit rules on 
benefit sharing and through mutually agreed terms an excellent platform for 
technology transfer. Private companies would on a contractual basis, 
established in good faith, contribute to the fulfilment of the obligation of the 
developed countries under TRIPs. To achieve those results it is necessary to 
create a binding legal network, on a global scale, where a PIC requirement 
would constitute an incentive towards compliance with national legislation 
governing ABS. However, a too heavy regulatory approach could stifle such 
development. The contract, with mutually agreed terms, flexible enough to 
adapt to the different capacities of parties, forms the suitable basis of a 
mutually beneficial bioprospecting venture. 
   The value of the voluntary guidelines or codes of conducts can be 
discussed. When the guidelines closely follow the CBD, with some 
elaboration, the main value would be that of contributing to good faith. One 
such example is the MOSAICC. The Code of Conduct aims to facilitate 
access and transfer to biological resources in a mutually beneficial manner. 
In providing for the basic requirements for any transfer to occur, access is 
made easy. Where more complicated (additional) terms are needed, it is 
explicitly stated that for any negotiations to succeed, they depend on the 
good will of the respective partners to reach an overall win-win situation 
and the mutual understanding of each other’s interest and the added value of 
                                                                                                                            
involved in those processes, but usually has important ecological function. Examples 
include antibiotics and pigments. http://en.wikipedia.org/wiki/Metabolites, 21/03/06. 
242 Greer, D, Harvey B, Blue genes: sharing and conserving the world’s aquatic 
biodiversity, 2004, p. 168f. 
243 Laird, S (ed), Biodiversity and Traditional Knowledge: Equitable Partnerships in 
Practice, 2002, p. 504. 
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respective contributions. The MOSAICC recognises that additional terms 
can involve different stakeholders such as local microbiologists, local 
competent authorities as well as representatives of local/indigenous 
communities. 
   Obviously a perception that prospecting can take place on mutually 
beneficial terms underlines this Code. The question is whether the PIC 
provided for in the Code enables such a win-win situation. Section II of the 
Code presents a model PIC application form. It refers to the CBD and 
accordingly PIC is applied for with the competent national authority. It does 
not refer to possible indigenous/local communities or other stakeholders that 
may need additional information presented in a way not only referring to the 
CBD. Although a welcome guideline, perhaps it would be beneficial to look 
beyond the wording of the CBD and adopt guidelines that anticipate 
national legislation’s requirement of a PIC procedure which includes 
suppliers of TK. Nevertheless, any attempt to provide clarity on the difficult 
concepts is laudable. 
   My final observation to conclude this thesis is that, when approaching this 
subject, it is too easy to end up going in circles. One issue cannot be 
separated from another making it very difficult to grasp the full picture. In 
this complicated situation, the bioprospector is placed. It is a fact that since 
1993, it is no longer legal to go to a country and pick up a small amount of 
soil to analyse back home. Access to biological resources must take place in 
compliance with national law, and in case of institutions sponsored by the 
state, in compliance with the CBD. It is therefore necessary, in the interests 
of the private sector to conduct business without undue burdens, and in the 
interest of countries, both developed and developing, to facilitate trade and 
development, for legislation governing IPRs and ABS to be sufficiently 
clear. A more pragmatic approach towards the issue, not influenced by the 
different discourses elaborated on in the introduction, would be preferable. 
In the mean time, while waiting for matters to develop through the continual 
enactment of legislation, it is advisable to make the extra effort. 
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7 Conclusion 
The possibility of exploring biodiversity to find novel compounds that 
potentially could cure serious diseases has by many been seen as a great 
opportunity. The image of the explorer, penetrating the deep jungle, 
obtaining knowledge from indigenous communities in order to pinpoint the 
plant with the medicinal properties, still remains viable. However, 
bioprospecting, the search, collection and screening of biological material 
and associated TK and for commercial ends has a much more pragmatic side 
to it. 
   This thesis has had the objective, in giving an overview of different 
aspects, legal and non-legal, to answer the question on how biological 
resources and associated TK is protected when accessed in bioprospecting 
activity. Acknowledging the fact that protection of TK is inextricably linked 
to IPR under TRIPs, and questions of ABS, and capacity-building of 
developing countries, the equal purpose of the thesis has been to closer 
analyse provisions governing these issues in international and national law. 
   The main conclusion to be drawn from the material has been that although 
many countries are in the process of enacting legislation, they are mainly the 
biodiversity-rich South countries. Equal measures are not taken in the 
developed North. This has led to the ongoing controversy regarding 
introduction of a PIC requirement into patent law, requiring an amendment 
to the TRIPs Agreement and to the enactment of national legislation that has 
been criticized for being to regulatory, thereby stifling bioprospecting 
activity and, as a consequence deterring the sharing of benefits accrued.   
   Another conclusion arrived to is the importance of capacity-building in 
terms of domestic competence in order to reap the benefits of a more 
stringent IPR system as under TRIPs. Developing countries are often left 
with having to provide for patent protection for advanced biotechnological 
inventions emanating from developed countries. There are no direct benefits 
for the developing countries to provide such protection if they are not able 
to take advantage of it on a domestic level. Who benefits from biodiversity 
depends not just on the power of moral arguments and of the law, but also 
on the power of knowledge. For a society to derive maximum benefits from 
its biodiversity, it must have at its disposal the tools of science and 
technology. But in many developing countries, particularly the smallest and 
poorest, scientific and technological expertise are notably lacking.  
   TK should be a source of welfare and invention for the people themselves; 
instead there are a number of cases where TK has been used to develop 
products where no benefits have been redirected to the providers of the TK. 
   On the other hand IPRs are vital for R&D based industries, the 
pharmaceutical industry being a classic example. For them bioprospecting is 
not a get-rich-quick scheme. It takes many years of analysis and testing that 
typically cost hundreds of millions of dollars. Many medicines that are 
developed from plant and animal extracts are a result of arduous research 
efforts, unexpected research results or trial-and-error experimentation. 
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Bioprospecting can be done responsibly. Development of products based on 
the genes, chemical compounds and structures of natural organisms can 
benefit not only consumers and commercial firms, but farmers, local 
communities and natural ecosystems as well. 
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Supplement A 
National case studies 
Even though the issue discussed in this thesis ultimately is transnational in 
its nature, it is also interesting to study how the issue is dealt with on a 
national level. How well can a developing country compete on an 
international market and at the same time protect its national resources in 
terms of biological resources and associated TK? 
Division of developing countries 
Bhagavan244 divides developing countries into three categories according to 
their science and technology. These countries are members either of the 
strong, medium or the weak South. The strong countries includes India, 
China, Mexico and Brazil, which are all moving into high-technology fields 
such as the third generation biotechnologies. The medium countries are 
above all Indonesia, Malaysia and Argentina, while the weak countries are 
those that are as technologically dependent on the developed countries now 
as they were before decolonization. 
 
India 
India is a rapidly developing country but also a country of mass poverty. 
However, it exports products that command a high price on the international 
market such as basmati rice and Darjeeling tea. The country also exports 
medicinal and aromatic plants, an industry that is rapidly expanding. On top 
of that, India has developed significant capacities in industrial chemistry and 
the life sciences. 
Biodiversity as such is important for all the socio-economic sectors of the 
population. A vast majority depend on biodiversity for their livelihood; it 
provides food and medicines and can be a tradable commodity.245 Only 
about 30 per cent of the population in India have access to 
pharmaceuticals246, and about 8000 plant species are used medicinally.247 
India is an important exporter of medicinal plants; however, medicinal 
plants and herbal formulations are sold for a much higher price in foreign 
markets than what Indian exporters receive. Hence there is scope for India 
                                                 
244 Bhagavan, M. R, ‘Introduction’ in Bhagavan M.R. (ed) New Generic Technologies in 
Developing Countries, Macmillan Press, Basingstoke, 1997, pp 3-4. 
245 Dutfield, Intellectual Property, Biogenetic Resources and Traditional Knowledge, 
Earthscan, London 2004, pp. 167-169. 
246 Lanjouw, 1998, The introduction of Pharmaceutical product patents in India: ‘Heartless 
Exploitation of the Poor and Suffering’?, NBER Working Paper No. 6366, National Bureau 
of Economic Research, Cambridge, p.23. 
247 Pradeep, 1998, "Making Science of Mumbo-Jumbo", 
http://ces.iisc.ernet.in/hpg/envis/doc98html/bioddo1124.html, 21/03/06. 
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to capture a greater value from this sector, which could be achieved through 
industrial refinement such as: 
 
• Isolating pure active compounds for formulation into drugs; 
• Isolating intermediates for the production of semi-synthetic drugs; or  
• Preparing standardized galenicals (extracts powders, tinctures, etc.)248 
 
This value would not necessarily stem from foreign markets. With a 
population of over one billion and a middleclass of about 200 million India 
could itself constitute a substantial market for many of these goods.249   
   India has Biodiversity legislation and separate IPR legislation enacted. 
The Patents Act, amended as of 2005, stipulates that non-disclosure of 
origin and the invention claim being anticipated having regard to TK in 
India or elsewhere constitute grounds for opposition.250 The Biodiversity 
Act prohibits anyone to apply for any IP protection, in India or elsewhere 
without the prior approval of the National Biodiversity Authority. The 
National Biodiversity Authority may impose benefit-sharing conditions 
upon the approval.251 Those benefit sharing conditions include joint 
intellectual property right to the National Biodiversity Authority or 
identified benefit claimers, transfer of technology, joint research or the 
location of research or production in India.252  
   India is one of the most advanced developing countries in terms of 
scientific capabilities. It has research capabilities in a broad range of 
biotechnologies and biotechnological applications which has attracted firms 
to set up R&D centres in India.253
   India has seen a number of high-attention cases where patents have been 
awarded abroad (mainly the US and the EU) for products and processes 
closely related to Indian TK. A classic example is the Neem-case or the 
Kani Tribe-case. There has also been profitable health products developed 
based on Indian TK, an example is reserpine, a tranquillizer and 
antihypertensive product derived from the medicinal plant Rauwolfia 
serpentine. Another Indian medicinal plant that have been the source of 
patents, one in the US254 and one European patent255, awarded to the Indian 
company Darbur for a polyherbal composition including extracts of  
Phyllanthus, is the niruri plant, Latin name Phyllantus amarus used for 
treating various ailments including jaundice.  
   However, with the present trend towards a growing domestic 
pharmaceutical industry, the Indian pharmaceutical companies are not 
primarily interested in natural product research as an approach to drug 
discovery. The Biodiversity Bill is making Indian biodiversity less 
                                                 
248 Dutfield, 2004, p. 170. 
249 Ibid.  
250 India, The Patents (Amendment) Act, No. 15 of 2005, Article 25.1 (j) and (k). 
251 India Biodiversity Bill, 2002, Bill No. 93-C of 2000, Chapter II, Article 6, (1) and (2). 
252 Ibid, Chapter V, Article 21 (2). 
253 Including the Swedish/British firm AstraZeneca, Dutfield, 2004, supra f.n. 246, p.175. 
254 US Patent No. 4673575, ‘Composition, pharmaceutical preparation and method for 
treating viral hepatitis’.  
255 EP0890360 ‘A polyherbal pharmaceutical composition useful in the treatment of 
conditions associated with hepatitis E and hepatitis B virus infections’. 
 79
accessible to foreign companies so it is likely that patents deriving from 
domestic biological resources will be held by Indians. This could serve as an 
encouragement to invest into natural product R&D.256  
 
Kenya 
Contrary to India, Kenya has patent protection somewhat more compatible 
to TRIPs. It has also provided for plant variety protection since 1972. 
Similar to India is the large export of natural products, some which benefit 
the national economy because of its high value in international markets and 
others that give no substantial benefits to the economy despite of the high 
market value.257  
   Kenya is not a megadiverse country such as India, however it is according 
to Kenya’s Ministry of Environmental Conservation, and the most species 
dense country in Africa.258 However, most of Kenya’s exports of natural 
goods are not natural products based on indigenous biological resources but 
rather resources introduced to Kenya during the colonial period (from the 
1880s to 1963).259 This means that natural compounds could represent a 
potential value added to the Kenyan economy. 
   Dutfield points out several disadvantages in comparison to India. Firstly 
there is very little invested into R&D, and it is only funded by government 
initiatives. The private sector is not involved. Technological capacities are 
limited with few qualified chemists who would benefit the country in terms 
of domestic R&D. In this environment, commercialization of TK is 
unlikely. In any case TK would only be exploited when no domestic 
capacity to make use of the knowledge exists. The likelihood of foreign 
corporations applying for patents in a manner more consistent with 
biopiracy than bioprospecting is more imminent. IP protection. When 
combined with early patent protection for chemicals, the lack of scientific 
graduates makes the situation non-beneficial for bioprospecting in Kenya. 
Without initial inventiveness in life-sciences patents do not provide for 
encouragement of invention.260 India is an example of taking advantage of 
weak IP protection in order to build up its domestic science and technology 
capacities to a point where stronger protection of IPRs can provide 
incentives for further invention. Kenya on the other hand has little to gain 
from allowing patent protection for all fields of technology as there are next 
to no domestic companies to benefit from that.261
 
 
 
                                                 
256 Dutfield, 2004, p.199. 
257 Ibid, p. 204.  
258 Kenya Ministry of Environmental Conservation, Draft First National Report to the 
conference of parties (COP), National Biodiversity Strategy and Action Plan, March 1998, 
p. 17. Available at: http://www.biodiv.org/doc/world/ke/ke-nr-01-en.pdf, 22/03/06. 
259 See e.g. http://www.unitedinternationalpress.com/Kenya/ken_i.html, 22/03/06. 
260 For an overview of the mutual development of life sciences and patent law see Dutfield, 
2003, Intellectual Property Rights and the Life Science Industries: A Twentieth Century 
History, Ashgate, Aldershot. 
261 Dutfield, 2004, pp. 217-218. 
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Supplement B 
The following is an extract from the GRAIN webpage: 
http://www.grain.org/nfg/?id=380, Last visited 01/05/06 
 
TK in free trade agreements, FTAs 
9 March 2006 
What does traditional knowledge have to do with "free trade"? It depends. 
For some people, traditional knowledge can be bought and sold, so it should 
have everything to do with it. For others, it's something to keep out of the 
market, so it should have nothing to do with it. Yet a lot of people are 
trudging around the middle grounds and ambiguities of this conflict. While 
trying to promote some sort of "rights" to traditional knowledge, they stay 
within the dominant framework of private property and usually end up 
proposing some adapted form of intellectual property rights. This makes it 
often misleading to speak of "protection" in relation to traditional 
knowledge. Protection of what? Corporate rights to exclude, own and sell? 
Or collective rights to use, share, improve and further develop knowledge in 
the context of local livelihoods? At the international level, governments 
have been debating whether and how to set up globally agreed rules on 
traditional knowledge for many years. This has been playing out at various 
institutions like the WTO, WIPO, the CBD and FAO, with occasional spats 
at UNESCO, the UN Commission on Human Rights or elsewhere. The 
debate, while technically boring and seemingly far removed from concrete 
realities, is actually fundamental. Smack in the centre is this monstrous 
ideological and cultural clash between looking at traditional knowledge as 
"intellectual property", thereby privatising it to serve corporate economic 
and development strategies, and looking at it as a collective heritage of 
peoples and communities that States have no business regulating, much less 
governing. While industrialised countries block any global agreement on 
this, because they're happy to profit from the commercial use of traditional 
knowledge without constraints, the pervasive neoliberal agenda of 
privatisation is slowly but steadily winning the day. To see it happening, we 
have taken a look at several of the bilateral and regional FTAs that 
governments are now signing like mad behind people's backs.  
 
Current patterns 
The issue of traditional knowledge has come up in a dozen or so FTA 
drafting processes over the last couple of years. In half of those cases, 
specific provisions on traditional knowledge were signed. While the limited 
number of experiences prevents us from drawing broad conclusions, there is 
a clear pattern currently at play.  
In all cases, the main concern expressed by governments trying to insert 
traditional knowledge into bilateral or regional free trade agreements is 
preventing or stopping its "misappropriation" ("biopiracy", as some people 
call it). And in all cases, they try to do this by proposing new twists and 
turns for rules on "intellectual property rights" (IPRs) such as patents, 
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copyrights, trademarks and geographical indications. At that point, however, 
one of two things happens, depending on whether or not the negotiating 
team across the table is the United States. All trade negotiators who manage 
to get traditional knowledge in an FTA discussion with the United States 
share the same plan: to create new mutually agreed rules and conditions on 
how corporations and public researchers get US patents on biodiversity and 
traditional knowledge coming from their own countries. These are typical 
"North-South" discussions: Peru facing the US; Colombia and Ecuador 
facing the US; Thailand facing the US; and 34 Latin American countries 
facing the US (plus Canada). In these cases, the proposals on traditional 
knowledge brought forward by the Southern government(s) amount to 
disciplining the grant of patents in the United States through special 
provisions on disclosure of origin, prior informed consent and benefit-
sharing related to the commercial use of genetic resources and traditional 
knowledge (see box 1). The US, not surprisingly, rejects this formula. Even 
if it wanted to accept it, which it does not, the US government is under 
politically-mandated "advice" from its biotech industry not to.  
When the "negotiating" partner across the table is not the United States, 
discussions take a different direction. All the FTAs in this category address 
the issue by acknowledging a role for independent systems of legal “rights” 
related to traditional knowledge. In some cases, this means devising 
common frameworks or tools among the countries involved. In other cases, 
the parties simply agree that each government may grant rights over 
traditional knowledge, and may potentially cooperate to that end, but 
without specifying common rules or tools 
 
Table 1: Some FTA processes addressing traditional knowledge  
SIGNED DEALS  STATUS  
Trans-Pacific Strategic Economic Partnership 
Agreement  
New Zealand , Brunei, Chile, Singapore  
Signed 3 June 2005  
In force as of 1 January 
2006  
New Zealand-Thailand Closer Economic 
Partnership Agreement  
Signed 19 April 2005  
In force as of 1 July 2005  
US-Dominican Republic-Central America 
Free Trade Agreement (US-DR-CAFTA)  
Dominican Republic , Guatemala, El Salvador, 
Honduras, Nicaragua, Costa Rica, USA  
Signed 5 August 2004  
Not yet in force  
US-Peru Trade Promotion Agreement  Signed 7 December 2005  
Not yet in force  
Economic Cooperation Organisation Trade 
Agreement (ECOTA)  
Afghanistan, Azerbaijan, Iran, Kazakhstan, 
Kyrgyz Republic, Pakistan, Tajikistan, 
Turkey, Turkmenistan and Uzbekistan  
Signed 17 July 2003  
Panama-Taiwan Free Trade Agreement  Signed 21 August 2003  
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UNDER NEGOTIATION OR IN 
PROCESS  
STATUS  
Free Trade Agreement of the Americas 
(FTAA)  
All countries of the American hemisphere 
except Cuba  
Since 1994. Last draft 
agreed in November 2003.  
US-Andean Trade Promotion Agreement  
Colombia , Ecuador and US, with Bolivia as 
observer. Peru was originally included.  
Since 2004. May end in 
individual bilateral 
agreements  
US-Panama Free Trade Agreement  Since 2004  
US-Thailand Free Trade Agreement  Since 2004  
Bay of Bengal Initiative for Multi-Sectoral 
Technical and Economic Cooperation 
(BIMSTEC-FTA)  
Bangladesh, Bhutan, India, Nepal, Sri Lanka 
and Thailand  
To come into force 1 July 
2006  
South Asia Free Trade Agreement (SAFTA)  
Bangladesh, India, Maldives, Nepal, Pakistan, 
Sri Lanka  
Was supposed to come into 
force 1 January 2006  
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